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Zusammenfassung
Die Genome von Mensch und Maus sind jetzt sequenziert. Diese bemerkenswerte
Errungenschaft drängt uns nun zum nächsten Schritt: die Entschlüsselung der
Genfunktionen. Um die Funktion eines Gens zu verstehen, ist es notwendig, die
Genexpression und in den Zellen zu studieren. Wir haben ein einzigartiges und
leistungsfähiges Werkzeug entwickelt, genannt GenePaint, mit dem wir die
Genexpression in Gewebeschnitten erfassen und dokumentieren können. Im Einzelnen
haben wir entwickelt und gebaut:
· einen Roboter  für die automatisierte In situ Hybridisierung von Gewebeschnitten im
Hochdurchsatzverfahren, der Daten mit zellulärer Auflösung erbringt,
· ein automatisiertes Hochdurchsatz-Dia-Abtastungsmikroskop zur Digitalisierung der
Genexpressionsmuster,
· sowie eine Datenbank  (GenePaint.org), die die kommentierten Genexpressionsmuster
zugänglich macht.
In dieser Studie wurden einzelne Bestandteile der GenePaint-Technologie geprüft,
sowohl Hardware als auch Reagenzien,  und  mit herkömmlichen Niedrigdurchsatz-
Verfahren verglichen. Bei herkömmlichen Methoden zur Expressionsanalyse, wie
Northern blot, sind die Informationen über die räumliche Verteilung der Genabschrift
(des Transkripts) minimal. Darüber hinaus kann sogar eine starke aber räumlich
begrenzte Expression eines Gens ein schwaches oder nicht erkennbares Signal im
Northern blot ergeben, wenn die Expression auf eine kleine Zellpopulation innerhalb des
Gewebes beschränkt ist. Mit unserem ISH-Verfahren werden Expressionsmuster in einer
einzelnen Zelle sichtbar gemacht; so steht ein Nachweis hoher Empfindlichkeit für die
Hochdurchsatz-Analyse der Genexpression zur Verfügung.
Um die Leistungsfähigkeit dieses integrierten Systems zu veranschaulichen, wurden alle
bekannten Mausorthologe der menschlichen Gene des Chromosoms 21 (HC21)
analysiert. Die Resultate der Expressionsanalyse sind jetzt öffentlich auf der Website
www.tigem.it/ch21exp/ zugänglich und seit kurzem auch in der GenePaint-Datenbank
unter www.genepaint.org vorhanden. Diese Studie zeigt, daß es jetzt möglich ist, die
Expressionsmuster aller Gene des Mausgenoms zu bestimmen. Folglich kann diese
Technologie für Genom-umfassende Studien der Genexpression verwendet werden, und
Zusammenfassung
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sie fügt eine neue Facette zur Ermittlung der Genfunktion hinzu. Wir werden nicht nur
Einblick in verschiedene pathologische Störungen gewinnen, sondern diese Technik
ermöglicht es uns außerdem, die Genregulation und die Netzwerke der Gene auf der
Ebene des Genoms zu verstehen.
Schlagworte: Menschliches Chromosom 21, Expressionsmuster-Analyse, Hochdurchsatz-
in situ- Hybridisierung.
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Abstract
The human and mouse genomes are now sequenced.  As a result of this remarkable
progress, the need to decipher gene function has become even more pressing.  To advance
understanding of gene function a necessary step is to study gene expression at tissue and
cellular levels.  We have developed a unique and powerful tool termed GenePaint to
study and document gene expression on tissue sections. Specifically we have:
· Constructed instrumentation for high-throughput, automated in situ hybridization on
tissue sections that yield data with cellular resolution.
· Assembled an automated high-throughput slide scanning microscope that digitizes
tissue sections and their gene expression patterns.
· Established a database (GenePaint.org) that makes accessible annotated gene
expression patterns.
In this study individual components of GenePaint hardware and chemistry were
thoroughly tested and were compared with conventional low-throughput procedures.
When using conventional methods such as northern hybridization to analyse expression,
the information on the spatial distribution of transcript is minimal. In addition, even
strong but localized expression of a gene may result in a weak or undetectable signal in
northern blots if expression is restricted to a small population of cells within the tissue.
Using our ISH and image acquisition system, expression patterns are revealed at a single
cell resolution; thus a high sensitivity assay is provided for high-throughput analysis of
gene expression.
To illustrate the power of this integrated system all known mouse orthologues of the
human chromosome 21 (HC21) genes were analyzed. The results of the expression
analysis are now publicly available at the website www.tigem.it/ch21exp/ and having
recently been uploaded onto the GenePaint database, are also available at
www.genepaint.org.  This study demonstrates that it is now possible to determine the
expression pattern of all genes of the mouse genome. Therefore this technology may be
used for genome-wide studies of gene expression, adding a new facet to the determination
of function. In turn this will not only allow us to gain insight into various disorders, but
will enable us to understand gene regulation and gene networks at a genomic level.
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Keywords: Human chromosome 21, expression pattern analysis, high-throughput in situ
hybridization.
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Foreword
To have worked on such a thesis project, has been a remarkable experience for a lot of
reasons but the greatest challenge was to actually absorb and interpret the massive
amount of data that was being produced. Collection of a lot of experimental data, which
was demanding, is usually the case when working with robotics.
This thesis thus presents the potential of the power of automated in situ hybridization,
how the data are produced, organized and stored for optimal retrieval. It is also illustrated
how the data can be accessed on web-based databases. Last but not least I discuss some
of the more obvious scientific implications of my work and how this may shape some of
the current views held in the field of genomics.
The need for an approach used in the present work  arrises from the vast amount of data
that needs to be examined as biology moves into the post-genomic era.
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Abbreviations
CPM Counts per minutes
DEPC Diethylpyrocarbonate
DNA Deoxyribonucleic acid
DNase Deoxyribonuclease
dNTP Deoxynucleotide
DS Down syndrome
DIG Digoxygenin
DTT Dithiotheitol
E14.5 Embryonic day 14.5
EDTA Ethylene diamine tetraacetic acid
HC21 Human chromosome 21
ISH In situ hybridization
IPTG Isopropyl-ß-thiogalactopyranoside
LB Lauria-Bertani medium
LCRs Locus control regions
mL Milliliter
min Minutes
NaAc Sodium acetate
NBT Nitro-blue tetrazolium
NTE Sodium tris EDTA
NTP Nucleotide
PCR Polymerase chain reaction
PK Proteinase K
PKC Protein kinase C
PMSF Phenylmethylsulfonyl fuoride
RNA Ribonucleic acid
RNase Ribonuclease
SDS Sodiumdodecylsulfate
TNT Tris sodium tween
Tris Tris[hydroxymethyl]-aminomethane
TSA Tyramide signal amplification
WBS Williams-Beuren Syndrome
X-Gal 5-bromo-4-chloro-3-indolyl-ß-galactosidase
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I. Introduction
The human and mouse genomes are now sequenced to an extent that had not been
expected until the middle of this decade (Lander et al 2001, Mouse Genome Consortium
2002). This provides us with an approximate gene content which is 30000 for the human
genome. As a result of this remarkable progress, the need to decipher gene function has
become even more pressing. To advance understanding of gene function it is necessary to
study gene expression at tissue and cellular levels. All the cells in our organism contain
the same genome codified in the DNA, but not all cells are the same: a neuron for
example, is very different from a blood cell or a muscle cell. This difference is due to the
fact that in each type of cell a different genetic program is activated, turning on or off
particular genes in various stages of embryonic development and adult-life. This
phenomenon is described with an appropriate term: it is said that cells “express” different
genes. This research has identified the expression-profile of the HC21 genes (see below),
that is to say, a catalogue of all the genes of HC21, which are either on or off in different
tissues during embryonic development. The outcome will eventually be a gene expression
atlas, depicting where (in which tissue) and when (at what stage of development) the
HC21 genes are expressed. The fact that a gene is expressed, at a particular stage of
embryonic development, in a specific tissue or organ, may indicate that this gene has a
function in that tissue (organ) or an important role in developmental regulation (Reeves
2002). The same is true even more so for pathological situations: if a gene is differentially
expressed in a pathological compared to a healthy cell, this suggests that it might be
implicated in the origins of the associated disease.
The cellular resolution of the non-radioactive RNA ISH technology presents the
opportunity to visualize gene expression within specific cells in a tissue which therefore
assists us in unraveling gene function.
1.1 Large scale expression analysis
To analyze the expression of genes by RNA ISH on a genome-wide scale, efficient
technologies need to be used to determine and represent expression patterns of thousands
of genes within an acceptable time scale. The objective here would be to scale-up the
existing conventional gene-by-gene analysis approach to a genome-wide scale. This
requires, high-throughput technologies that allow the determination (automated solvent
delivery platforms) and visualization (automated microscopy) of the gene expression
Introduction
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patterns on tissue sections by RNA ISH at cellular resolution. The instrumentation used in
this study was developed in our laboratory, where a catalyzed reporter deposition
(CARD) based signal amplification technique, which improves the sensitivity of the non-
radioactive ISH protocol, was adapted to the robotic platform (Bobrow et al. 1989).
Although there have been previous large scale whole mount ISH studies which provide
the spatiotemporal distribution of transcripts (Strachan et al. 1997, Neidhardt et al. 2000,
Bulfone et al. 1998, Gawantka et al. 1998), this study is the first large-scale application of
the automated non-radioactive ISH  technique on tissue sections.
The technology required for automated high throughput ISH experiments on tissue
sections and the machinery for automated high resolution microscopy that makes it
possible to acquire images of a large number of specimens is outlined in Figure 1. For the
efficient storage and retrieval of scientific data, web-based databases are excellent
instruments. Therefore, a database has been developed that can provide all these features.
The task of the database is to be able to import and store data (images and experimental
metadata) and, when required, to allow retrieval of the data in an efficient manner (Visel
et al. 2002).
Mouse embryonic day 14.5  was chosen because of the detailed expression information
one can acquire from whole embryo sections. Unlike earlier stages, E14.5 mouse
embryos show relatively well developed organs and tissues. The mouse is an excellent
model organism both because it is easy to collect specimens and because it is a species
with a well characterized genome suitable for the study of human biology (Bradley 2002,
Smithies 1993). Being a mammal and having similar genetic and physiological systems,
when compared to human, it only shows a difference in size and shape. Not only do the
whole organ systems in the mouse show the same structure but also homeostatic
equilibria, reproduction and behavioral parallels are observed (Bradley 2002). This causes
many pathological conditions to arise in a similar manner in both species. Most human
mutations and genetic diseases cause the same defects to show up in the mouse. On the
other hand if the same phenotype is not observed when a defect is caused in the mouse
orthologue gene, as is the case for the cystic fibrosis gene, the reason for this effect to not
arise could give an answer on how to prevent the problem from occurring in humans.
Another important reason favoring the mouse over other animals is that the laboratory
mouse is tractable. One must not also forget that today the scientific community is
experienced in manipulating the mouse genome. Today it is also possible to acquire ES
cells of genes knocked-out via a gene trap approach from consortiums around the globe.
Introduction
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Figure 1. Flowchart representing the non-radioactive ISH procedure (GenePaint). The
procedure has distinct elements, each of which can be automated to a considerable extent.
Modified from Herzig et al 2001.
A systematic analysis of spatiotemporal gene expression patterns  carried out in Xenopus
during early development indicated that the identification of ‘synexpression groups’;
genes with a shared complex expression pattern, can predict an association of genes to
specific molecular pathways (Gawantka et al. 1998). Gawantka and coworkers have
systematically analyzed 1765 randomly picked cDNAs by whole mount ISH.
Although we are able to utilize today -in principle- the whole mouse genome, when
initializing this thesis project, it was necessary to concentrate on a well mapped region of
Obtaining the RNA probe
a. preparation of template cDNA
b. synthesis of RNA probe
Preparing the sample tissue
a. harvesting of embryos
b. sectioning of embryos and pre-treatment of tissue
Automated in situ hybridization
a. prehybridization, probe hybridization, posthybridization steps
b. color detection reaction
Automated image acquisition
 a. scanning of specimen with microscopy
b. assembly of 2D images with mosaic software
Image and data storage
a. transfer of images to database
b. entry of metadata containing tables of experimental parameters
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the human/mouse genome. Nearly the whole (99.7%) of human chromosome 21q had
been sequenced by May 2000 and was publicly available, making it a very good object
for our study (Hattori et al. 2000).  Chromosome 21q represents ~1% of the human
genome. The whole sequence of HC21 recently followed that of chromosome 22q
(Dunham et al. 1999).  Being correlated to an important disease like DS is one of the
reasons why HC21 has played a leading role in the Human Genome project. A dense
linkage map was first prepared for HC21 (McInnis et al. 1993), later a HC21 NotI
restriction map was developed and the size of the long arm was estimated to be around 34
megabases based upon pulse-field gel electrophoresis studies using restriction fragments
(Ichikawa et al. 1993). Today a 99.7% coverage of chromosome 21q has been achieved
and 281,116bp have been sequenced from the short arm, where analysis of the base
composition has revealed 178 confirmed genes and 36 predicted genes (Hattori et al.
2000, Annatorakis 2001, Davidson et al. 2001, Pletcher et al. 2001, Reymond et al.
2002a, Reymond et al. 2001). The mouse syntenic regions (conserved chromosome
blocks containing orthologue genes which are consecutively ordered in an identical
manner across species), which are segments of mouse chromosomes 10, 16 and 17
containing the mouse orthologues of the HC21 genes, harbor 170 orthologue genes
(Figure 2). In other words the regions of  homology that correspond to the human
chromosome 21 are distributed on three different mouse chromosomes. 199 cDNA
fragments representing 150 mouse orthologues (more than one fragment for some genes)
were isolated for ISH experiments. This study demonstrates that it is now technologically
feasible to determine the expression pattern of all the genes of the mouse genome.
1.2 Diseases related to chromosome 21
An extra copy of HC21 causes Down syndrome (DS) which affects 1 out of 700 live
births and is the cause of severe mental retardation (Wiltshire et al. 1999).  HC21 is the
second smallest chromosome after human chromosome 22, containing approximately 200
genes, but its study is of enormous importance for research on DS and for a considerable
number of other genetic diseases such as myopathy, anemia, blood platelet disorders,
sclerosis, heart rhythm problems, one form of epilepsy, at least two forms of deafness and
two types of cataracts (Hattori et al. 2000). The symptoms of DS are complex and involve
various organs: the most frequent characteristics are mental retardation, low stature, short
limbs, oblique palpebral fissures (upward slant to the eyes), protruding tongue, cardiac
defects (present in 40% of the patients), a higher incidence of leukemia and defects of the
Introduction
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Figure 2. The synteny between human chromosome 21 and mouse chromosomes 16 (blue), 17
(green) and 10 (red) are depicted.  All the known mouse orthologues of the HC21 genes are
dispersed across three syntenic regions on three mouse chromosomes.
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immune system (Epstein 1995). Furthermore, the amyloid beta precursor protein gene is
localized on HC21, and this gene has been related to Alzheimer’s disease. It is known
that people with DS have early onset Alzheimer with higher frequency. Mutations in 14
known HC21 genes have been identified as the cause of monogenic disorders including
one form of Alzheimer’s disease (APP), amyotrophic lateral sclerosis (SOD1),
autoimmune polyglandular disease (AIRE), homocystinuria (CBS) and progressive
myclonus epilepsy (CSTB). Loci for the following diseases which have been associated to
a HC21 gene (due to mutations observed in patients) do not have their mouse orthologues
pinpointed yet; recessive non-syndromic deafness (DFNB10 and DFNB8) (Bonne-Tamir
et al. 1996, Veske et al. 1996), Usher’s syndrome type IE (Chaib et al. 1997), Knobloch
syndrome (COL18A1, Sertie et al. 1996), Bethlem myopathy (COL6A1, Jobsis et al.
1996), Ullrich disease (COL6A2), long QT6 (KCNE2) and holoprosencephaly type I
(HPEI) (Estabrooks et al. 1990). The expression atlas of  HC21 will give us a more
precise insight on the role of these genes, which, to a large extent, is still unknown.
Partial duplication and deletions of other chromosomes exist, but only a few trisomies of
whole chromosomes have been known to survive. The reason for their higher survival
rate might be the lower density of genes present in HC21. Trisomies of other
chromosomes are mostly embryonic lethal. Trisomies have been reported for
chromosomes 13 and 18, but are observed at a much lower frequency compared to
trisomy 21 (Beaudet et al. 1995). At present, no treatment to cure or prevent DS exists.
The current care provided for the patients, though important, can only monitor and
correct some of the symptoms such as those related with cardiac defects, and
rehabilitation therapy which aims to support  harmonic development and a good
scholastic, social and professional integration.
Loss of heterozygosity was observed for specific regions of HC21 in several solid tumors
(Sakata et al. 1997, Kohno et al. 1998, Ohgaki et al. 1998, Yamamoto et al. 1999,
Ghadimi et al. 1999, Bockmuhl 1998) including cancers of the head, neck, breast,
pancreas, mouth, stomach, esophagus, and lung. Loss of heterozygosity occurs when one
allele of a gene is inactivated, in most cases through a mutation or chromosomal deletion,
thus resulting in the loss of the functional allele. This usually indicates that there is at
least one tumor suppressor gene in this region. Recently it has been shown that AML1-
ETO can suppress transcription of the p14arf tumor suppressor, through inactivation of the
AML1 (RUNX1; located on HC21) DNA binding site of the p14arf  promoter (Linggi et al.
2002). The decreased incidence of tumors in DS individuals indicates that an increased
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dosage of HC21 genes may protect the cells of these individuals from transformation
(Satge et al. 1998a, Hasle et al. 2000).
Due to the fact it is currently not feasible to carry out research on gestation or early
gestation  periods in humans, interest has turned to animal models. One approach was to
create a segmental mouse trisomy model;  this would be done by creating a segmental
mouse trisomy for chromosome 16. Most of the HC21 genes are harbored on the mouse
chromosome 16 syntenic region, which makes it the appropriate chromosome to be used
in a mouse model representing the trisomy 21 disease state. Ts65Dn is a segmental mouse
chromosome 16 trisomy that shows male sterility and degeneration of the cholinergic
neurons of the basal forebrain (Reeves et al. 1995). A limitation of the Ts65Dn mouse is
that the mouse chromosome 16 trisomy segment harbors more than just the HC21
orthologue genes. Another perspective would be to individually analyze  genes by
developing transgenic mouse models where the increased dosage of HC21 genes can be
examined. Data from transgenic mice indicate that a subset of genes on HC21 may be
involved in the phenotypes observed in DS patients (Kola and Herzog 1997).
In humans it is not known which and how many of the HC21 genes are important to
cause the symptoms and signs of the syndrome. The expression atlas of HC21 is an
important instrument for connecting the expression of these genes with the various
symptoms of DS. It also gives us insight to which and how many genes are involved in
the origins of this disease. For example, some of the genes of HC21 are expressed in
particular regions of the heart during embryonic development; therefore these genes may
have a role in congenital heart defects found in Down patients. In the same way, some
genes that are expressed in the embryonic limbs like Adamts1 and Erg, might be involved
in hand and feet anomalies typical of the syndrome. Finally, a set of HC21 genes are
expressed in the brain, suggesting that they may play a role in mental retardation. Having
studied E14.5 mice which correspond to human mid embryonic stages will allow this
study to provide significant information on which HC21 genes could be important for the
correct development of organs which especially have developmental defects in DS.
1.3 Relationships existing between expression patterns and the organization
of the genome
The significance and importance of the expression pattern and the annotation atlas of the
HC21 genes in relation to genetic disorders is obvious. The illnesses occurring through
mishaps that affect the genes or gene clusters located on HC21 will be pinpointed,
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eventually allowing us to prevent or treat these diseases. Different from any previous
studies, an expression pattern analysis of a whole chromosome presents the opportunity
to explore whether there might be a relationship existing between the organization of
genes on a chromosome and the expression pattern of these genes. The reading of the
genome requires that its individual components are correctly organized to permit the
proper readout and hence a natural development of an organism. To achieve this, the
genome needs to synchronize and influence its components through communication
carried out across various levels of hierarchy. This could be done through the co-
regulation of genes belonging to shared regulatory pathways, owing to shared non-coding
sequence motifs that direct the binding of specific groups of shared transcription factors
(Li et al. 1999). Several of these sequence motifs are similar to cis-regulatory elements
found in the regulatory regions of other known developmentally regulated genes. Thus
genes localized across the genome involved in the same genetic network would be
regulated in harmony due to shared regulatory elements. The Hox family of genes, which
play a crucial function in the patterning of the body, are another example where a non-
random organization of the genes in the genome is observed. The Hox genes are clustered
as a block of genes on one chromosome (Boncinelli et al. 1993). Analysis of the sequence
of the 5' region of the Hox genes has allowed the identification of known sequences
capable of interacting with transcription factors (Awgulewitsch et al. 1990). Therefore the
consecutive placement of genes could allow their coordinated regulation through a
regulatory element. This is due to the fact that the parallel transcription of these genes
might be simultaneously required at a certain stage of development.
However, beside the known classical elements like promoters, classical enhancers,
chromosomal insulators and matrix or scaffold attachment regions, there is the probability
that the co-regulation of genes might be in response to Locus Control Regions (LCRs) (Li
et al. 1997, Schreiber and Bernstein 2002). LCR confer high level, tissue specific,
integration site independent, copy number dependent expression on linked transgenes
(Pennacchio and Rubin 2001).  Further studies are required to asses this mode of gene
regulation, but attention needs to be drawn to the point that our expression data for  HC21
provides the basis of such work. Hence through this study we not only wish to elucidate
the pathogenesis of diseases but we expect to gain insight into novel mechanisms of gene
control.
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II. Materials and Methods
2.1 Materials
Table 1. The chemicals and kits were purchased from the following companies.
Product Supplier
[a32P] dCTP Amersham Pharmacia
Agarose Fluka
Ampicillin Sigma
Ampuwa sterile water Fresenius
Anti-DIG-Fab-POD Roche
Bacto-Agar Difco,  USA
Bacto-Yeast Extract Difco
BCIP Roche
Big dye terminator Mix PE Applied Biosystems
Bisbenzimide (Hoechst) Sigma
BMB blocking reagent Roche
Bromphenolblue Sigma
BSA, bovine serum albumin Sigma
Calciumchloride Biomol
Chloroform Roth GmbH, 76185 Karlsruhe
Deckgläser, 24x55, No1, Superior Marienfeld
Dextran sulfate Sigma
Dnase I (RNase free) Roche
DNTPs Roche
DTT, dithiothreitol Sigma
EDTA Sigma
Ethanol Roth GmbH, 76185 Karlsruhe
Ethidium bromide Sigma
Ficoll, MW 400,000 Sigma
Formaldehyde Electron Microscopy Sciences
Formamide Calbiochem
Glutaraldehyde, 25% Lösung Merck, 64271 Darmstadt
Glycerin Gibco BRL
Glycin Sigma
Hydrochloric Acid, HCl, 1N solution Roth GmbH, 76185 Karlsruhe
Hydrogen Peroxide Fluka
Hydro-Matrix Micro-Tech-Lab
ISH Buffer Ambion
Iodoacetamide Sigma
IPTG Biomol
Kaiser's glyceringelatine Merck, 64271 Darmstadt
Kb-Ladder NEBiolabs
KH2PO4 Merck, 64271 Darmstadt
Levamisole Sigma
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Liquid scintilation cocktail (Ready Flow III) Beckman
Maleic Acid, disodium salt, anhydrous Fluka
Methanol Roth GmbH, 76185 Karlsruhe
Microscope slides Menzel Gläser
Na2HPO4 Riedel de Haen
NBT Roche
NEN blocking reagent NEN/Perkin-Elmer
NEN tyramide signal amplification kit NEN/Perkin-Elmer
NeutrAvidin-AP Pierce
Phenol Roth GmbH, 76185 Karlsruhe
Plasmid-Miniprep-Kit Qiagen, USA
Polyvinylpyrrolidone, PVP Sigma
Potassium Chloride, KCl Roth GmbH, 76185 Karlsruhe
Proteinase K Roche
Restriction enzymes NEBiolabs
Reverse Transcriptase Invitrogen
RNase A Sigma
RNase Inhibitor Roche
RNaseZAP Sigma
Salmon-Sperm-DNA Sigma
SDS Serva
Select Peptone Gibco BRL
Sheep Serum Chemicon International Inc.
Sodium Chloride, NaCl Roth GmbH, 76185 Karlsruhe
Sodium Hydroxide, NaOH, 1N solution Roth GmbH, 76185 Karlsruhe
T3-RNA-Polymerase Roche
T4-DNA-Ligase Gibco BRL
Taq-DNA-Polymerase Qiagen, USA
Tissue-Tec (OCT) Sakura
Triethanolamine Fluka
Tris Roth GmbH, 76185 Karlsruhe
Trisodium citrate dihydrate Roth GmbH, 76185 Karlsruhe
Tween-20 Sigma
X-Gal Biomol
Yeast tRNA Roche
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2.2 Methods
2.2.1 Isolation of nucleic acids
2.2.1.1 Mini preparation for plasmid DNA isolation
Minipreps were prepared by inoculating a single E. coli colony into 4mL of LB medium
containing the appropriate antibiotics (ampicillin or kanamycin, 50µg/µL), in 15mL
sterile culture tubes by using a sterile toothpick or loop and incubated overnight in the
shaker (300rpm) for 16-18 hours at 37°C. After preparing a glycerol stock of each culture
(200µL glycerol+ 800µL culture),  the samples were centrifuged at 1400g for 15 min at
4°C. After removing the supernatant, the bacterial cell pellet  was resuspended in 100µL
of resuspension buffer P1 and transferred into Eppendorf tubes. Then, 150mL of lysis
buffer P2 was added into the samples and mixed gently by inverting 4-6 times, followed
by the addition of  150mL of neutralization buffer P3 and mixed immediately but gently
by inverting 4-6 times. The cells were then centrifuged (25 min at 12,000g, at 4°C). After
centrifugation, the protein and chromosomal DNA pellet was discarded and the
supernatant containing  plasmid DNA was transferred into a new Eppendorf tube. The
plasmid DNA was precipitated by adding 1mL of 100% Ethanol (0.7 volumes) and
centrifuged (25 min at 12,000g, at 4°C), the pellet was further washed with 1mL of  70%
ethanol. The pellet was dried at room temperature and dissolved in 30µL water. "Qiagen
Plasmid Midi Kit" (Qiagen, USA)  buffers were used in this procedure.
2.2.1.2 Midi preparation of  plasmid DNA isolation
In order to isolate a larger amount of plasmid DNA, the midi preparation DNA isolation
method was carried out. For this purpose, the "Qiagen Plasmid Midi Kit" (Qiagen, USA)
was used. 50µL of miniprep culture (as described in 2.2.2.1.) was used to inoculate 50mL
LB medium containing the appropriate antibiotics (ampicillin or kanamycin, 50µg/µL)
and incubated overnight in the shaker (300rpm) for 16-18 hours at 37°C. After preparing
a glycerol stock of the culture (200µL glycerol+ 800µL culture),  the bacterial suspension
was centrifuged at 1400g  for 15 min at 4°C, and the pellet was then resuspended in 4mL
of Buffer P1 . For the cell lysis, 4mL of  Buffer P2 was added, then mixed gently but
thoroughly by inverting 4-6 times, the suspension was incubated at room temperature for
5 min. 4mL of Buffer P3 was added to neutralize the suspension and mixed by inverting
the tube. The suspension was centrifuged at 12,000g for 30 min and the supernatant
applied to a previously equilibrated Qiagen-tip100 column (by applying 10mL of Buffer
QBT for column equilibration) and left to run through the column resin by gravity flow.
The column was washed twice with 10mL of Buffer QC. The DNA was eluted with 5mL
of Buffer QF, and precipitated by adding 3.5mL (0.7 volumes) of isopropanol. Which
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was then centrifuged immediately at 12,000g  for 30 min at 4°C. The pellet was  washed
with 70% ethanol, air dried for 10 minutes at room temperature and dissolved in 50µL
water. The DNA concentration was subsequently determined  with a photometer, (see
2.2.2).
2.2.2 Determination of the nucleic acid concentration
The concentration of DNA or RNA was determined photometrically (8452A photometer,
Hewlett Packard, Hamburg) by measuring absorption of the diluted sample, at 260nm and
320nm (control). The concentration was calculated according to the following formula:
C  =  ( E260 - E320 ) x f x c
C  =  concentration of the sample (µg/µL)
E260 =  absorption at 260nm
E320 =  absorption at 320nm
f  =  dilution factor
c =  concentration(standard)/absorption(standard)
for double stranded  DNA;  c  = 0.05µg/µL  and for RNA; c  = 0.04µg/µL
2.2.3 Restriction of  DNA
For the specific digestion of  plasmid DNA, type II restriction endonucleases were
essential. These enzymes are capable of recognizing, binding and cleaving short defined
nucleotide sequences in the target DNA. The restriction of the DNA was carried out in a
defined buffer system, when multiple enzymes were used, a single buffer system such as
"One -phor-all" (Amersham Pharmacia) was used. Digestion of DNA was carried out for
1- 2 hours at optimal temperature. One unit of enzyme is enough to cleave 1µg of DNA
(having a single cleavage site) in 1 hour at 37°C. In a 20µL reaction, the following
components were added:
1µg   DNA
2µL   10x  reaction buffer
1µL    enzyme (10 units)
xµL    H20
20µL (total volume)
2.2.4 Ligation of  DNA fragments
The ligation of foreign DNA fragments into vectors was carried out in the following
reaction mix and the reaction was incubated overnight at 16°C. Although various ratios
may be set up for a better chance of ligation, the vector to fragment ratio is usually 1:3.
30ng    digested vector DNA
90ng    foreign DNA fragment
2µL       T4 DNA ligase enzyme (5U/µL)
4µL       5x ligation buffer
xµL      H2O
20µL    (total volume)
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2.2.5 Transformation of competent bacterial  cells
A 50µL volume of competent cells (E.coli DH5a or TOP 10 cell) were mixed with 5-
10µL of ligation reaction and placed on ice for 30min. The transformation reaction was
then incubated at 42°C for 90 sec and placed on ice for 2 more minutes. In order to
accelerate bacterial growth, 200µL of LB medium was added to the suspension which
was incubated at 37°C for 45 min. After incubation, 100-150µL of the suspension was
spread on the appropriate plate (Oja or kanamycin plate). The plate was incubated
overnight at 37°C. The selection of a positive colony  was carried out with  the blue-white
screening method.  The insert containing  colonies were  white, while  the others were
blue (when the bluescript vector was used).
2.2.6 Preparation of  LB medium and LB agar plates
2.2.6.1 LB medium
For 500mL LB medium, 5g tryptone, 2.5g yeast extract and 5g NaCl were dissolved in
450mL of deionized water. The pH of the solution was then adjusted to 7.2 with 5M
NaOH, and the volume increased to 500mL with deionized water. The sample bottle was
autoclaved for 25 min on liquid cycle. After autoclaving and cooling, the necessary
antibiotics were added.
2.2.6.2 LB agar plate with kanamycin
For the preparation of 500mL LB agar, 5g tryptone, 2.5g yeast extract, 5g NaCl and 7.5g
agar were dissolved in 450mL deionized water, then pH was adjusted to 7.2 and finally
the volume was completed to 500mL by deionized water. The LB agar medium was
autoclaved for 25 min, left to cool to approximately 55°C. After adding 1mL of  IPTG
(100mM) and 500mL of  Kanamycin (50 mg/mL), the medium was poured into Petri
dishes. The plates were stored at 4°C, if not used immediately.
2.2.6.3 Oja plate
500mL LB agar was autoclaved, then it was left to cool to approximately 55°C, the
antibiotic, such as 500µL of Ampicilin (100mg/mL) and other components: 1mL of  X-
Gal (2%) and 1mL of  IPTG (100mM) were added. The mixture was poured into Petri
dishes and stored at 4°C.
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2.2.7 Agarose gel electrophoresis
Non-denaturing gel electrophoresis was employed for the separation of restricted DNA.
The concentration  of the gels used, varied between 0.8% and 2% agarose content (w/v)
in 0.5x TAE buffer. The TAE buffer was also used as electrophoresis buffer.
The agarose was dissolved in the buffer by boiling. The solution was slowly cooled, then
2.5mL of ethidium bromide (0.5mg/mL) was added and poured into the gel bed. Before
loading samples, 0.2 volume of stop mix (loading buffer) was added and mixed. The
samples were then loaded into the wells of the gel and electrophoresis was carried out at a
steady voltage (50 or 100 volts).
2.2.8 Polymerase Chain Reaction (PCR)
A typical PCR reaction was conducted as follows. Amplification of target sequences was
carried out by mixing the following:
5µL            10x PCR buffer
10µL           5x Enhancer
1µL             10mM dNTP (50x)
2µL             upstream primer (10pmol)
2µL             downstream primer (10pmol)
variable µL DNA (50-250ng)
0.4µL           Taq DNA Polymerase (2U)
variable µL H20
50µL  (total  volume)
The reaction was carried out in an Eppendorf, thin walled PCR tube (200µL). The
Eppendorf PCR cycler used for the reaction had a heated-lid (105°C) which prevented the
reaction volume from changing due to evaporation. First the target DNA was denatured
by heating the reactants at 95 0C for 2 min. This is followed by 35 cycles:
20sec - 94°C (denaturation), 20sec -  55°C (annealing), 1min - 72°C (extension) (1min
per 1000 base-pairs)
The last elongation step was extended to 9 min. After finishing the PCR, 5mL of the
reaction was mixed with loading buffer and run on a 1.5% agarose gel.
2.2.9 Non-radioactive dye terminator cycle sequencing
The non-radioactive sequencing was achieved with a Dye Terminator Cycle Sequencing
Kit (Applied Biosystems) and the reaction products were analyzed with automatic
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sequencing equipment, namely a 377 ABI Prism DNA Sequencer (Applied Biosystems).
For the sequencing reaction, four different dye labeled dideoxy nucleotides were used.
These, when exposed to an argon laser, emit fluorescence which could be detected and
interpreted. The reaction progressed in a total volume of 10mL containing 1mg plasmid
DNA or 100-200ng purified PCR products, 10pmol primer and 2mL reaction mix
(contains dNTPs, dideoxy dye terminators and Taq DNA polymerase). Elongation and
chain termination took place during the following program in a thermocycler: 5 minutes
denaturing followed by 25 cycles of; 95°C 15 sec, denaturing; 55°C 15 sec, annealing;
70°C 4 min, elongation. After the sequencing reaction, the DNA was precipitated with
1/10 volume Na Acetate and 2.5 volumes 100% ethanol. After washing the pellet with
70% ethanol to remove the salt, the pellet was air dried and then dissolved in 3mL of
loading buffer, denatured at 90°C for 2 min, and finally loaded onto the sequencing gel.
2.2.10 Reverse transcription
1-5µg total RNA was mixed with 1µL of oligo (dT)16-18 primer (500 µg/mL) in a total
volume of 10µL. Synthesis of cDNA was carried out with the ThermoScriptTM RT-PCR
System, Invitrogen.
Mix1
Oligo(dT)-Primer 1µL
RNA up to 9µL (1µg/µL)
Depc-treated water up to  9µL
To avoid the possible problems with secondary structure of the RNA which might
interfere with the synthesis, the mixture was heated to 70°C for 10 minutes, and then
quickly chilled on ice.
Mix2 (for one probe)
5x cDNA Synthesis Buffer     4µL
0,1M DTT 1µL
RNaseOutTM (40U/µL) 1µL
Depc-treated water 1µL
10mM dNTP-Mix 2µL
Vortex and mix, mix1 and mix2 and after heating to 42°C for 2 minutes add 1µL
ThermoScriptTMRT (15U/µL). Incubate for 60 min at 42°C in a water bath.   Stop the
reaction by heating to 70°C for 15min. Add 1µL RNase H (10U/µL) and incubate 20min
at 37°C. Place on ice.
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2.2.11 Quantitative PCR and the determination of detection sensitivity
To evaluate our detection sensitivity we chose a gene showing low ubiquitous expression
throughout the tissue. The Dscr3 gene was a suitable candidate for this purpose.  The
outline of the experiments conducted are presented in Figure 3.
2.2.11.1 Preparing P7 mouse brain sample for mRNA extraction
The expression pattern for the Dscr3 gene was observed to be ubiquitous in the near-
rostral portion of a postnatal P7 mouse brain. The brain was dissected out of the skull and
the piece of brain tissue corresponding to the region of interest was collected after the rest
was removed with a razor. Three P7 brain specimens were collected in this manner from
NMRI litter mates. One brain (specimen Y; 193mg) was embedded in OCT for later cryo-
sectioning. The other specimens were reserved for DNA (specimen 1; 189mg) and RNA
(specimen 2; 196 mg) extraction.
Figure 3. The diagram presents an outline of the experiments carried out to estimate the
sensitivity of the instrumentation. The mRNA was isolated with Dynabeads as explained
(2.2.11.2) and the standard was prepared using the Ambion competitor synthesis kit. The cell
number was determined in one of the parallel sets after the approximate estimation of the cell
radius.
2.2.11.2 RNA isolation from specimen
The mRNA was isolated from the 193mg brain tissue using the Dynabeads Oligo (dT)25
procedure as suggested by the manufacturer (Dynal Biotech). After initial isolation of the
mRNA from the lysate, a second round of fresh Dynabeads were incubated with the
mRNA isolation
from whole sample
(unknown concentration)
cDNA synthesis
Synthesis of appropriate
competitor mRNA
(4.2869x109 copies/µL)
cDNA synthesis
Real-time PCR
Sectioning of
one of the
parallel brain
samples
(8 parallel sets) Count cells in one brain specimen
2µL
2µL
dilutions
estimation of # of cells
in one set
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lysate to ensure all the mRNA was captured. The mRNA concentration was determined in
a spectrophotometer and run on a gel to assess its quality.
2.2.11.3 Radioactive in vitro transcription
The Ambion Competitor Construction Kit was used to obtain high yields of in vitro
transcription products in the 300-500 nucleotide range. As described by the manufacturer
the following reaction cocktail was prepared:
1 µg template DNA in a volume not to exceed 5µL
2 mL 10x Transcription buffer
2 mL 5x (2.5mM ATP, GTP, 2' modified CTP and UTP)  NTP solution
2 mL T7 RNA polymerase (20U)
<5 mL RNase-free dH2O
0.4µL [a-32P] ATP (10mCi/mmol) (Amersham Pharmacia Biotech)
20 mL total volume
The contents were mixed, and incubated at 37°C for 4 hours. 1µL was removed to a
scintillation vial with appropriate cocktail. The removal of template DNA was carried out
with DNase I (5U/µL) incubation as described by the manufacturer. Competitor was
purified by running on a 5% acrylamide gel and extracted from the gel as described by
the manufacturer. Finally the competitor was eluted in 15µL of nuclease free water and
1µL was transferred to a scintillation vial.
CPM readings were taken in a LKB Wallac 1209 Rackbeta Liquid Scintillation counter.
The Beckman Ready Flow III Liquid Scintillation Cocktail was used for the procedure.
CPM readings were taken for 60 seconds. Using the formula specified by manufacturer
the copy number for the competitor was determined:
CPM/µL of purified competitor RNA    x     3x1014 molecules of ATP/µL   
CPM/µL of transcription reaction # of A's in the competitor RNA
5578.1            x    3x1014      =   4.2869x1010 copies of competitor RNA/µL 
339452.2     115
2.2.11.4 Determination of Dscr3  mRNA concentration
The Dscr3 gene was analyzed using the following PCR primer set: Dscr3 (Dscr3F:
AACTGCGCTATCACGCAGC;  Dscr3R: TCCTGTTGCATTCCAGACG). The first
strand cDNA was synthesized with oligo-dT primers (Thermoscript RT-PCR System,
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Invitrogen). 1µL of mRNA (total elution volume of isolated mRNA: 30µL) was
incubated with primers and dNTPs at 65°C for 5 minutes before cooling on ice. After
adding 4µL of the appropriate buffer, 40U of RNase inhibitor and 2µL of 0.1 M DTT, the
volume was adjusted to 19µL with RNase free water. The RT mix was incubated for 2
minutes at 42°C, and then 1µL Thermoscript reverse transcriptase was added  (15U/µL)
(Thermoscript RT-PCR System, Invitrogen). The RT reaction was incubated at 42°C for
60 minutes and then stopped by heating at 70°C for 15 minutes. The reaction was
incubated with 1 µL RNase H (10U/µL) (Thermoscript RT-PCR System, Invitrogen) for
20 minutes at 37°C.
Real-time PCR was carried out using 2µL of the cDNA. To analyze the Dscr3 RNA a
standard was generated. To construct the standard, the same primers used for Real-time
PCR were used. To amplify the Dscr3 specific fragment the following PCR conditions
were used;  denaturation for one cycle at 94°C for 2 minutes, 35 cycles of 94°C for 15
seconds, 56°C for 15 seconds, 72°C for 30 seconds and a final cycle at 72°C for 10
minutes. The PCR reaction was carried out in 25µL with final concentrations according to
manufacturer’s protocol (1 x PCR buffer, 1x Q-solution, O.5U Taq polymerase, Taq PCR
Core Kit, Qiagen) and sufficient dNTPs (0.5µL of 50x PCR Nucleotide Mix, Roche). The
Taq polymerase was added after the 2 minute denaturation step. Amplified fragments
were sub cloned into a vector pCRII-TOPO (Invitrogen). The orientation of the fragment
was checked via sequencing. The pCRII-TOPO vector was used to prepare a DNA
template, by PCR, that was sequenced and  used to generate RNA by in vitro
transcription according to the manufacturer’s protocol (RT-PCR Competitor Construction
Kit, Ambion). The RNA was purified, the concentration measured and the copy number
was calculated. (see 2.2.11.3)
The Real-time PCR amplification was carried out in an iCyler iQ (Biorad) to determine
the mRNA copy number for the Dscr3 gene in the tissue sample. The PCR reaction
(50µL) was set up according to the manufacturer’s protocol (IQ SYBR Green Supermix,
Biorad), with 1µL template (standard with a known copy number or cDNA). The reaction
was carried out under the following condition in the iCycler: denaturation for one cycle at
95°C for 3 minutes, 45 cycles of 95°C for 30 seconds, gradient 53.5-56°C for 30 seconds,
72°C for 30 seconds where the real-time analysis was carried out at 72°C. The PCR
products were checked by electrophoresis to confirm that a single PCR product was
obtained. After a preliminary run using standards with 10 fold serial dilutions an
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optimized run that was bracketing the unknown sample was done with 2 fold serial
dilutions to generate the standard curve.
2.2.11.5 Isolation of DNA from Mouse Brain Sample
After the brain specimen was prepared (as described above), it was placed into an
Eppendorf  tube, then  700mL of lysis buffer and 35mL of Proteinase K (10mg/ml) were
added. The sample was homogenized and incubated at 37°C for 1 hour. 350mL of phenol
and 350mL of chloroform was added and sample was centrifuged at 12,000g for 10min, at
4°C. The upper phase was transferred to a new Eppendorf tube and 1 volume of
chloroform was added. The sample was centrifuged and later the upper phase transferred
to a fresh tube. 1/10 volume of Na Acetate (3M, pH 8) and 0.7 volume of isopropanol
were added and  the same centrifugation step was carried out. The pellet was washed with
1mL of  70% ethanol and then dried at room temperature. At the end, the pellet was
dissolved in 100mL of  1x TE buffer.
2.2.12 cDNA's representing the mouse orthologues of the HC21 genes
We translated the putatively encoded proteins from the HC21 confirmed genes. These
strings of residues were used to “tblastn” search the non-redundant database for
orthologous murine cDNA sequences. We identified corresponding murine ESTs using
the “blastn” program with the above isolated longest murine cDNAs as search queries.
HC21 predicted genes and HC21 confirmed genes with no orthologous cDNA sequences
in Genebank were compared directly to murine dbEST sequences to identify putative
orthologous EST sequences. The availability of the Celera Genomics mouse genome
sequence (http://www.celera.com/) allowed us to confirm that the identified ESTs/cDNAs
were representative of the murine orthologues of the HC21 genes by in silico mapping.
HC21 shows conserved syntenies to mouse chromosome (MC) 16, 17 and 10
(http://www.informatics.jax.org/). As the human ITSN gene encodes a long and a short
alternatively spliced transcript with ubiquitous and brain-specific expression (Guipponi et
al. 2001), we collected and analyzed by ISH different murine ESTs specific for each
form. In addition because ERG and its paralogue Fli1 are extremely similar at the DNA
level, we performed ISH with probes for both genes to assure that the ERG probe staining
was specific. The different IMAGE and BMAP EST clones used in this study were
obtained from Research Genetics (www.resgen.com). The National Institute of Aging
provided the laboratory with the NIA 15K Mouse cDNA Clone Set and the Japanese
National Institute of Infectious Diseases the NIID clones. To confirm the identity of the
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cDNA, each clone was subjected to 5’ and 3’ end sequencing on an ABI377 or an ABI
PRISM3100 (Applied Biosystems). As no murine ESTs were available for the C21orf13,
C21orf29, C21orf57, C21orf68, C21orf83, C21orf95, Cldn17, Erg, Pred53, Prss7, Slc5a3
and Uromodulin-like orthologues, we generated probes for these genes by RT-PCR from
different normal murine tissues, cloned into a pCRII-TOPO vector (Invitrogen) and
sequenced. Human and mouse comparative mapping of HC21, MC16, MC17 and MC10
was used to design specific primers in highly conserved regions. The evolutionary
breakpoints lie between ZNF295 and UROMODULIN-like (MC16/MC17 breakpoint) and
inside the PDXK gene (MC17/MC10) (Davidson 2001). Consistently the ESTs/cDNAs
representing orthologues of human genes mapping between the centromere and ZNF295
map to MC16, the ones corresponding to the human genes mapping between
UROMODULIN-like and KIAA0179 map to MC17, and those analogous to the human
genes mapping from PDXK to the telomere map to MC10, for three of the genes there is
ambiguous information about the mouse orthology. A noteworthy exception is the H2bfs
gene. H2BFS, a histone H2B family S member, maps to 21q22.3 just centromeric from
KIAA0179, and another copy of this gene maps to 6p21. It is likely that the latter
represents the ancestral copy from which the other copy arose through a duplication
event, as the murine orthologous gene maps to MC13, in a region syntenic with 6p21.
Only one gene was reported to map on the short arm of the acrocentric HC21, the TPTE
gene (Hattori et al. 2000). The human TPTE gene is present in multiple copies in the
human genome, but the active copies are thought to lie on 21p, 13 and 15q. Its murine
orthologue was mapped to a region of MC8 that shows conserved synteny with human
13q14.2-q21. This region of the human genome contains a partial and highly diverged
copy of TPTE that is likely to represent the ancestral copy from which the other copies of
TPTE arose through duplication events (Reymond et al. 2001). The attempts to amplify
large cDNAs fragments of the Znf298 and Slc37a1 were unsuccessful.
All the 199 probes for the HC21 orthologous mouse genes have been sequenced and
along with various other metadata the images of expression patterns are publicly available
at the website www.tigem.it/ch21exp/ and in the www.genepaint.org database. All known
HC21 genes are presented in Table 2 in their chromosomal order.
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Table 2. All verified human chromosome 21 genes
Gene
human gene
accession #
mouse ortholog
accession # Clone library clone accession chromsome probe+
TPTE/PTEN2 NM_013315 AJ311311      
C21orf15 AY040090       
PRED5 AP001660       
RBM11 AP001660 BB633189 UIMBH21ape-h040UI BMAP BE648228 MC16 4G6
   clone 183  M.L.Y lab MC16 4H12
PRED6 AP001660       
STCH NM_006948 AK021006 1907602 IMAGE AI226564 MC16 1H6
SAMSN1 NM_022136 NM_023380 3822366 IMAGE BF660993 MC16 2B4
RIP140/NRIP1 NM_003489 NM_008735 408685 IMAGE AI893344 MC16 1F5
USP25 NM_013396 NM_013918 3708890 IMAGE BE569282 MC16 4C11
   3597996 IMAGE BE533229 MC16 4C12
C21orf34/C21orf35 AP001666       
CXADR NM_001338 NM_009988 H3135F11 NIA 15K BG087114 MC16 1D11
BTG3 NM_006806 NM_009770 1515802 IMAGE AW823883 MC16 1H2
C21orf91/YG-81 NM_017447 AK005829 1495644 IMAGE AI664407 MC16 5A1
   4482610 IMAGE BG242627 MC16 4G7
   H3025B10 NIA 15K BG078224 MC16 4G5
C21orf68/PRED12 AK022689 AK014255 clone nb 6  RT-PCR MC16 3G8
PRSS7 NM_002772 NM_008941 clone nb 9  RT-PCR MC16 3G11
PRED14 AP001679       
NCAM2 NM_004540 NM_010954 UIMBH2.2aop-e120UI BMAP BE649879 MC16 4G12
   clone 130  M.L.Y lab MC16 4H8
PRED15 AL163227       
C21orf42 NM_058184       
MRPS39/C21orf8/MRPL39 AK000458 AF239728 1514828 IMAGE AW913227 MC16 1H1
JAM2/VE-JAM/C21orf43 NM_021219 NM_023277 1195543 IMAGE AA690843 MC16 3C3
   UIMBH0ajqe050UI BMAP BE656219 MC16 3C2
ATP5J NM_001685 NM_016755 H3115C02 NIA 15K BG085594 MC16 1C11
   3512913 IMAGE BG277264 MC16 4C1
GABPA NM_002040 NM_008065 1282513 IMAGE AA866905 MC16 1G7
APP NM_000484 NM_007471 H3132G02 NIA 15K BG086954 MC16 1D10
C21orf95/CYYR1 AY061853 AY061854  300 bp, clone nb 6  RT-PCR MC16 4G4
ADAMTS1 NM_006988 NM_009621 H3034B07 NIA 15K BG078965 MC16 1B5
ADAMTS5 NM_007038 NM_011782 569515 IMAGE AA288689 MC16 3E7
N6AMT1/PRED28 NM_013240 AK013667 3971724 IMAGE BF714407 MC16 2H2
KIAA0714/ZNF294 AB018257  1329026 IMAGE AA929353 MC16 3D5
   1516272 IMAGE AW824144 MC16 3D4
C21orf6 NM_016940 NM_016924 3484719 IMAGE BE286595 MC16 2A11
USP16 NM_006447 NM_024258 H3152C04 NIA 15K BG075823 MC16 4A1
CCT8 NM_006585 NM_009840 H3018A08 NIA 15K BG077645 MC16 1A8
C21orf7 AY033900 AY033899 1153184 IMAGE AA645026 MC16 3C1
BACH1 NM_001186 NM_007520 3599795 IMAGE BE380232 MC16 3C7
GRIK1 NM_000830 X66118 UIMBH1ann-a030UI BMAP BE864009 MC16 1E11
CLDN17 NM_012131       
CLDN8 NM_012132 NM_018778 H3064H02 NIA 15K BG081413 MC16 2H1
PRED29 AP001709  608371 IMAGE AA162070 MC16 4H10
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Gene
human gene
accession #
mouse ortholog
accession # Clone library clone accession chromsome probe+
TIAM1 NM_003253 NM_009384 2609690 IMAGE AW320557 MC16 3E3
   3412641 IMAGE BE633001 MC16 3E4
SOD1 NM_000454 M35725 H3130B11 NIA 15K BG074045 MC16 1D8
SR-A4/KIAA1172 AF023142 U49058 Rn3 779633 IMAGE AA466932 MC16 3E2
HUNK/MAK-V NM_014586 NM_015755 H3010H08 NIA 15K BG077115 MC16 1A6
C21orf45 NM_018944 AK012533 3825587 IMAGE BF715138 MC2 4E2
   3383880 IMAGE BG145540 MC2 4E3
C21orf61        
KIAA0539/C21orf108 NM_014825  3976165 IMAGE BG146293 MC16 4H3
   1092114 IMAGE AA670781 MC16 4H7
C21orf63/PRED34 AF358258 AF358257 UIMAO0aby-g-120UI BMAP BE652074 MC16 1E12
C21orf59 NM_021254 AK003413 3654930 IMAGE BF011432 MC16 4A11
   4191729 IMAGE BF539818 MC16 4B7
SYNJ1 NM_003895 NM_053476 3470497 IMAGE BF023103 MC16 3G10
C21orf66 AY033903 AY033907 10F7R-H  RT-PCR MC16 2G3
   10F1R-B  RT-PCR MC16 3E11
   10F9R-Q  RT-PCR MC16 3E12
C21orf62/PRED36 NM_019596 AK016554 1264334 IMAGE  MC16 4F6
RACK17/OLIG2 XM_047941 AB038697 UIMBH0ait-d060UI BMAP AI854441 MC16 1F1
IFNAR2 NM_000874 NM_010509 3600669 IMAGE BE381041 MC16 2F2
CRFB4 NM_000628 NM_008349 3994647 IMAGE BF167015 MC16 2C1
IFNAR1 NM_000629 NM_010508 H3118F09 NIA 15K BG085842 MC16 1C12
IFNGT1/IFNGR2 NM_005534 NM_008338 1531332 IMAGE AW988781 MC16 1H4
C21orf4 NM_006134 BC004841 H3137H08 NIA 15K BG087296 MC16 2G7
RPS5L NM_001009 HC19 NM_009095 H3112G03 NIA 15K BG072599 MC7 1C8
   H3112G04 NIA 15K BG072599 MC7 1C9
GART NM_000819 NM_010256 H3047B10 NIA 15K BG079975 MC16 1B9
SON/C21orf50 AF380179 NM_019973 H3035B06 NIA 15K BG065775 MC16 1B6
DONSON/C21orf60 NM_017613 AF193608 1314881 IMAGE AA929739 MC16 2E2
CRYZL1 NM_005111 AK008846 H3123G05 NIA 15K BG073533 MC16 1D6
   1531726 IMAGE BE134049 MC16 4C8
ITSN NM_003024 NM_010587 3156638 IMAGE AW910367 MC16 2A4
ITSN long form AF064244 NM_010587 1246139 IMAGE AA823724 MC16 3C4
ITSN short form AF064243 NM_010587 313401 IMAGE AI414524 MC16 3C5
ITSN short form   419417 IMAGE W88185 MC16 3C6
ATP50 XM_009742 AF254738 697411 IMAGE AA230539 MC16 1F12
C21orf101/MRPS6 AY061855 AY061856 H3100H09 NIA 15K BG084441 MC16 4E4
SLC5A3 NM_006933 NM_017391  1162 bp, clone nb 1  RT-PCR MC16 4G3
KCNE2 NM_005136 AK008619 UIMBH1aly-e-030UI BMAP BE864913 MC16 4D12
C21orf51 AY033902 AY033901 3152735 IMAGE BE553636 MC16 2E11
PRED38 AP001720       
KCNE1 NM_000219 NM_008424 1222885 IMAGE AA667912 MC16 2D11
DSCR1 NM_004414 NM_019466 639212 IMAGE AA200984 MC16 4E6
CLIC6 AF448438 AF448440 1511135 IMAGE AW990844 MC16 1G12
RUNX1 NM_001754 NM_009821 4008335 IMAGE BF135151 MC16 2C3
C21orf18 NM_017438 AY037804 717391 IMAGE AI466884 MC16 3G4
   H3104D09 NIA 15K BG071899 MC16 1C5
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Gene
human gene
accession  #
mouse orthologue
accession  # Clone library clone accession chromsome probe+
CBR1 NM_001757 NM_007620 3986613 IMAGE BF120878 MC16 2B6
C21orf19 AF363446 AF363447 H3015D11 NIA 15K BG077443 MC7 2G11
   3468606 IMAGE BF682834 MC7 2E12
CBR2/CBR3 NM_001236 AK003232 1066729 IMAGE AA611976 MC16 1G3
C21orf5 NM_005128 NM_026700 849213 IMAGE AI481251 MC16 2D4
KIAA0136 D50926  3470826 IMAGE BF023393 MC16 2F1
CAF1A NM_005441 AK011243/BC013532 3981861 IMAGE BF100487 MC16 2F7
   3995650 IMAGE BF165815 MC16 2C2
CLDN14 NM_012130 NM_019500 1431432 IMAGE AI042730 MC16 1G9
SIM2 NM_005069 NM_011377 3168352 IMAGE BE457094 MC16 2A5
HLCS NM_000411  455800 IMAGE AA023801 MC16 3E9
DSCR6 NM_018962 AB063284 H3111B09 NIA 15K BG085288 MC16 2G6
DSCR5 NM_016430 NM_019543 3470896 IMAGE BF023450 MC16 2A10
TPRD/TTC3 NM_003316 NM_009441 H3004A06 NIA 15K BG063181 MC16 1A2
DSCR3 NM_006052 NM_007834 H3007H01 NIA 15K BG063488 MC16 1A4
   2780726 IMAGE AW743140 MC16 1H12
DYRK1A NM_001396 U58497 3988308 IMAGE BF162516 MC16 2B8
KCNJ6 GIRK2 NM_002240 NM_010606 UIMBH3aul-h-110UI BMAP AW494400 MC16 2H8
DSCR4 NM_005867       
IRKK/KCNJ15 NM_002243 NM_019664 4234899 IMAGE BF782321 MC16 3H10
ERG M17254 AB073078 749 bp, clone nb 6  RT-PCR MC16 4G1
ERG   821 bp, clone nb 9  RT-PCR MC16 4G2
FLI (ERG paralogue) NM_002017 NM_008026 808955 IMAGE  AA467723 MC9 1G1
ETS2 NM_005239 NM_011809 4021851 IMAGE BF143562 MC16 2F11
C21-LRP/DSCR2 NM_003720 AJ238270 H3129G11 NIA 15K BG086724 MC16 1D7
   3972244 IMAGE BF722699 MC16 4C9
   3970373 IMAGE BF722174 MC16 4C10
N143 AJ002572       
WDR9 AJ292465 AJ292467 3657672 IMAGE BG100363 MC16 4A12
HMG14/HMGN1 NM_004965 NM_008251 H3120G04 NIA 15K BG086014 MC16 1D4
WRB NM_004627  4021269 IMAGE BF142081 MC16 2C8
C21orf13 AL163279  650 bp, clone nb 7  RT-PCR MC16 5A5
SH3D1A/SH3BGR NM_007341 NM_015825 586149 IMAGE AA138480 MC16 1F10
B3GALT5 NM_033173 NM_033149 MNCb-0324 NIID AU067673 MC16 3E10
IGSF5 AL163280  4917803 IMAGE BG863468 MC16 4G8
   4236489 IMAGE BF784177 MC16 4G9
   1513545 IMAGE AW990468 MC16 4H6
PCP4 NM_006198 NM_008791 UIMAH0acw-a110UI BMAP AI839872 MC16 3D8
DSCAM NM_001389 NM_031174 614553 IMAGE AA170935 MC16 4D1
BACE2 NM_012105 NM_019517 313341 IMAGE AI605601 MC16 2C9
C21orf11 AJ409094 AF360358 1546160 IMAGE BE135671 MC16 2E8
MX2 NM_002463 NM_013606 3374009 IMAGE BE629286 MC16 4H4
MX1 NM_002462 NM_010846 4020700 IMAGE BF143741 MC16 2C7
TMPRSS2 NM_005656 NM_015775 4017848 IMAGE BF168078 MC16 2C6
   3979313 IMAGE BF102443 MC16 2F5
C21orf83 AY063456 NM_023663 850 bp, clone nb 3  RT-PCR MC16 5A3
ANKRD3/DIK/PKK NM_020639 NM_023663 3979359 IMAGE BF102436 MC16 2B5
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Gene
human gene
accession  #
mouse orthologue
accession  # Clone library clone accession chromsome probe+
ZNF298 AP001745       
C21orf25 AL163290  4017776 IMAGE BF168443 MC16 2C5
ZNF295 NM_020727  3156533 IMAGE AW910268 MC16 2A3
UROMODULIN-like AP001745  668 bp, clone nb 2  RT-PCR MC17 5A4
ABCG1/WHITE NM_004915 NM_009593 3988239 IMAGE BF159563 MC17 2B7
TFF3 NM_003226 NM_011575 1166710 IMAGE AA710846 MC17 2D9
   1545811 IMAGE BE136788 MC17 1H5
TFF2 NM_005423 NM_009363 438574 IMAGE AI894032 MC17 1F7
TFF1 NM_003225 NM_009362 493047 IMAGE AI893383 MC17 2D1
TMPRSS3 NM_024022 AJ300738 Lung 1.1  RT-PCR MC17 3E5
UBASH3A NM_018961 AK020009 3375785 IMAGE BE627812 MC17 2A7
TSGA2 AK057315 NM_025290 H3075A12 NIA 15K BG082335 MC17 1B11
SLC37A1 NM_018964       
PDE9A NM_002606 NM_008804 3326827 IMAGE BE456255 MC17 2A6
WDR4 NM_018669 NM_021322 4009256 IMAGE BF138291 MC17 2F8
   671843 IMAGE AA242309 MC17 1F3
NDUFV3 NM_021075 BC013640 3465040 IMAGE BE687712 MC17 2A8
PKNOX NM_004571 NM_016670 3415880 IMAGE BE687087 MC17 3G6
CBS XM_033010 BC013472 H3079G04 NIA 15K BG082744 MC17 3C11
   H3079G12 NIA 15K BG082752 MC17 3C12
U2AF1 NM_006758 AK012849 H3086D11 NIA 15K BG070353 MC17 1B12
CRYAA NM_000394 J00376 355457 IMAGE W48180 MC17 htgs 2C11
   420571 IMAGE W90910 MC17 htgs 1F6
HSF2BP NM_007031 AK016553 H3125B05 NIA 15K BG086370 MC17 4A3
SNF1LK AP001751 NM_010831 1260296 IMAGE AA855274 MC17 3D11
H2BFS NM_017445 AK011516 3465513 IMAGE BE688921 MC13 2A9
   1531132 IMAGE AW988475 MC13 2E7
KIAA0179 XM_035973 AK011155 H3020A05 NIA 15K BG064464 MC17 1A9
PDXK NM_003681 NM_031769 H3013B08 NIA 15K BG077257 MC10 1A7
CSTB NM_000100 NM_007793 421131 IMAGE W91030 MC10 3D2
NNP1 NM_003683 NM_010925 H3158F11 NIA 15K BG088875 MC10 1E9
AGPAT3 NM_020132 NM_053014 H3158D09 NIA 15K BG088853 MC10 1E8
TMEM1 NM_003274 AC009295 H3108A09 NIA 15K BG085049 MC10 2H6
PWP2 NM_005049 AK018333 4015754 IMAGE BF143119 MC10 2F9
C21orf33/HES1 NM_004649 NM_008235 H3139H01 NIA 15K BG074828 MC10 1D12
KIAA0653 AB014553  H3103C07 NIA 15K BG084637 MC10 1C4
DNMT3L NM_013369 AJ404467 H3094C02 NIA 15K BG084050 MC10 1C2
   1295738 IMAGE AA919800 MC10 4C3
AIRE NM_000383 NM_009646 1282549 IMAGE AI510675 MC10 2G4
   1265557 IMAGE AI552580 MC10 2G5
PFKL NM_002626 NM_008826 H3025D11 NIA 15K BG064930 MC10 1A12
C21orf2 NM_004928 BC010330 H3158A06 NIA 15K BG088819 MC10 2G9
TRPC7 NM_003307 AJ344343 1195195 IMAGE AA718075 MC10 4E9
C21orf102/LRRC3 AY061857 AY061858 693205 IMAGE AI466988 MC10 4E11
HSM801110 XM_036086       
C21orf29 AP001754  857 bp, clone nb 4  RT-PCR MC10 5A2
C21orf31 AP001754       
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Gene
human gene
accession  #
mouse orthologue
accession  # Clone library clone accession chromsome probe+
PRED53 AP001754  clone nb 6  RT-PCR MC10 5A6
KAP AL163300 NM_010670 1197995 IMAGE AA727102 MC10 2D10
UBE2G2 NM_003343 NM_019803 4021048 IMAGE BF143429 MC10 4B4
   4038176 IMAGE BF181354 MC10 4B5
SMT3H1 NM_006936 NM_019929 H3023B06 NIA 15K BG078058 MC10 1A11
C21orf1 NM_004339  H3044B12 NIA 15K BG079708 MC10 2G10
ITGB2 NM_000211 NM_008404 3593958 IMAGE BE377951 MC10 2B1
C21orf67 AF380178       
C21orf69 AY035381       
C21orf70/PRED56 AF391113 AF391115 3515288 IMAGE BG370650 MC10 3G2
ADARB1 NM_015833 AF403109 976454 IMAGE AA619858 MC10 3H7
C21orf80/KIAA0958 NM_015227 AK009301 3991098 IMAGE BF163502 MC10 3H9
   2136258 IMAGE AI956321 MC10 1H7
COL18A1 NM_030582 NM_009929 H3111D11 NIA 15K BG085302 MC10 1C6
SLC19A1 NM_003056 NM_031196 1399806 IMAGE AI115777 MC10 1G8
PCPB3 NM_020528 NM_021568 918000 IMAGE AI596471 MC10 2D5
COL6A1 NM_001848 NM_009933 H3151F07 NIA 15K BG088322 MC10 1E4
COL6A2 NM_001849 X62332 H3152G04 NIA 15K BG088405 MC10 1E5
FTCD NM_006657 BC010813 1277595 IMAGE AA880297 MC10 2D12
C21orf56 AP001759  3664026 IMAGE BF319576 MC10 4G10
   515785 IMAGE AA066026 MC10 4G11
   514002 IMAGE AA062323 MC10 4H5
OSC/LSS NM_002340 U31352 Rn H3037A02 NIA 15K BG065929 MC10 1B7
MCM3AP NM_003906 NM_019434 H3031B12 NIA 15K BG078720 MC10 1B4
C21orf57 AY040873  clone nb 4  RT-PCR MC10 5A8
C21orf58 AY039243       
PCNT NM_006031 NM_008787 H3078B07 NIA 15K BG069605 MC10 4E12
KIAA0184 D80006 AK019853 3497934 IMAGE BE303319 MC10 2A12
S100B NM_006272  1380986 IMAGE AI035528 MC10 4A8
HSM800390 AL050065       
HRMT1L1 NM_001535 AF169620 574888 IMAGE AA120755 MC10 1F8
Color code for table;
Not  done.
No murine probes.
No murine orthologue.
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2.2.13 RNA detection by automated in situ hybridization: instrumentation for high
throughput gene expression analysis
RNA ISH has been used since the mid 1980’s. The principle to this method is simple,
where tissue or sections of tissues are probed with tagged synthetic DNA or tagged anti-
sense RNA. The RNA detection by ISH procedure for this study is a multi step procedure
consisting of steps that have been extensively optimized throughout the years. The
technique consists of the following consecutive main steps:
· preparation of sample and fixation of tissue
· pretreatment of sample that has been mounted onto microscope slides
· hybridization of the probes
· post hybridization washes to remove non-specifically bound probe and detection of
the hapten-labeled probe
· microscopic analysis of the sample, image acquisition and image archive
All the glassware used in this procedure have been baked at 180°C overnight and all
solutions used in the steps prior to post hybridization washes are DEPC treated to prevent
RNA degradation, where later solutions are only prepared with ultra-pure water. The
current study has been carried out with 14.5 day old embryos but can be applied to other
developmental stages and tissues.
After the plug is observed, a NMRI mouse is sacrificed on the afternoon of the 14th day.
The day the plug is observed is presumed to be day 1. The embedding is done into
optimal freezing medium (OCT) as explained below. The chambers used for this purpose
have a copper plate bottom which is placed onto an aluminum surface that is cooled down
to -70°C (Herzig 2001). The embryo is placed into the freezing chamber, orientated and
then placed onto the aluminum surface which cools the chamber through the copper base.
Consequently the chamber gradually freezes from the bottom, preventing the shock
freezing of the tissue, which might be the cause of damage due to pressure accumulating
at the core, resulting from expansion from the surface inwards. This could be the result of
rapidly freezing samples in liquid nitrogen. Orienting the embryos is very important for
obtaining stereotaxic sections, with a consistent or near consistent line of plane. In Figure
4 Nissl stained E14.5 embryos are shown, where you can see that the main organs of the
body are represented. Only organs like the pancreas and spleen are still primordial.
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Figure 4.  Nissl stained E14.5 embryos. In the above figure it can be seen that the major organs
of the body have developed. Especially those of importance when looking for genes involved in
Downs syndrome, like the brain, heart, limbs, gut and the thymus.  This stage corresponds to mid
embryonic human periods, giving it critical importance in our search for genes of developmental
importance.
a. Preparation of the sample and fixation of tissue:
1. Freshly isolated embryos of the appropriate stage were dipped into ice-cold
phosphate buffered saline (PBS, 0.137M NaCl 0.0027M KCl 0.01M Na2HPO4
0.002M KH2PO4 pH 7.4) to wash away the blood. They were then transferred to ice-
cold OCT and kept there for 5 minutes. All the steps are carried out on ice.
2. The embryo was transferred to an OCT embedding chamber, where they were frozen
slowly. This was carried out with a freezing chamber specially designed for this
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purpose, which has a copper plate bottom that was in contact with an aluminum
surface at -70°C.
3. The embryo was sectioned (20µM thick) with a Leica CM3050S cryostat (Germany)
with a sample temperature of -12°C and chamber temperature of -17°C. Sections
were placed in appropriate positions on a Super Frost Plus microscopy slide
(Germany). (see Figure 5 Cryostat)
4. The tissue on the slides was fixed for 20 minutes with 4% paraformaldehyde (PFA)
(EMS, USA) in PBS solution. Then the slides were washed in PBS twice to remove
the fixative.
5. The tissue was acetylated for 5 minutes (2x) with acetylation solution (0.25% acetic
anhydride, 0,1M triethanolamine, pH 8.0, Sigma, Fluka respectively).
6. The tissue on the slides was refixed for 20 minutes with 4% Para formaldehyde
(EMS, USA) PBS solution. The slides were then washed for 5 minutes in PBS to
remove the fixative, transfer to 0,9% NaCl for 5 minutes and dehydrate the cells in a
graded series of ethanol (30%, 50%, 70%, 80%, 95% and 2x 100%) 2 minutes each
step at room temperature. (Automated) (Figure 5 Autostainer XL)
7. The slides were air dried. Slides are storable for up to 3 months at –80°C in air tight
dessicated chambers.
Figure 5.  On the left you can see the Leica CM3050S cryostat, the Leica autostainer XL can
be seen on the right.
A liquid handling system retrieves and delivers buffers and reagents from receptacles
placed next to the racks. Figure 6 depicts a Tecan Genesis platform adapted to the ISH
protocol. The software controlling the platform is Gemini V3.2. Using this equipment
with two racks (2 x 48 hybridization chambers), pre-hybridization, hybridization, post-
hybridization and the hapten labeled probe detection steps were carried out automatically
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with little human intervention or supervision. One run took approximately one day, where
a daily throughput yielded as many as 380 sections.
Slides carrying the tissue sections were integrated into a flow through chamber (Figure
6). This device constitutes a small flow-through chamber with a 400mL reservoir on top,
an 80mm thick chamber housing the tissue (volume; 120mL) and an exit for solutions on
the bottom. Solutions filled into the well enter the narrow hybridization chamber by
gravity and remain in place due to capillary forces until displaced by a fresh solution
filled into the well. Eight such platforms are arranged into a row and six rows constitute a
48 position rack (Figure 6). In this setup the slide of the hybridization chamber directly
contacts the surface of the platform permitting efficient thermal transfer.
Figure 6. A Tecan Genesis platform modified to carry out automated high-throughput in-situ
hybridization. (A) Genesis RSP 150 platform, (B) one of the two racks containing 48 places for
hybridization chambers, eight such platforms are arranged into a row and six rows constitute a 48
position rack, (C) hybridization chamber with a 400mL reservoir on top, an 80mm thick chamber
housing the tissue (volume: 120mL) and an exit for solutions at the bottom and (D) signal observed
on tissue sections at higher magnification (Npy).
B A
C D
Solutions are
delivered to the
reservoir
Space
r
Microscopy slide
(holding tissue)
Backplate Clamp
s
Frame
Materials and Methods
41
b. Pretreatment of the sample that has been mounted onto microscope slides (Automated):
Unless otherwise stated all the following pretreatment steps were at room temperature.
Allow slides to thaw before opening air tight chambers.
1. The slides mounted into slide chamber were treated, 6 times for 5 minutes with
300mL of MeOH solution (Roth) containing 0.6% hydrogen peroxide (Fluka). The
slides were then washed 8 times with 300mL of PBS with 0.05% Tween20.
2. Then the slides were treated 2 times for 4 minutes with 300mL of 0.2N HCl with
0.05% Tween20. Next the slides were washed 8 times with 300mL of PBS with
0.05% Tween20.
3. The slides were treated 2 times for 7 minutes with 300mL of Proteinase K in buffer
(with appropriate concentration corresponding to the stage of tissue to be treated)
(50mM TRIS, 5mM EDTA, pH 8.0) with 0.05% Tween20. The slides were then
washed 8 times with 300mL of PBS with 0.05% Tween20. Mild protease treatments
have a positive effect on detection efficiencies and should be optimized depending on
tissue type and concentration for each application.
4. Then the slides were treated 2 times for 10 minutes with 300mL of 4% PFA in PBS
solution with 0.05% Tween20. The slides are then washed 8 times with 300mL of
PBS with 0.05% Tween20. This step is very important for the retention of RNA and
the preservation of cellular morphology, but its is critical to not over do this step to
make sure too much cross linking does not prevent RNA accessibility.
5.  Finally the probes were pre-hybridized with ISH Buffer (Ambion, Cat. # B8807G)
for 30 minutes at 60°C.
c. Hybridization of the probes (Automated):
The probes used for transcript detection vary according to the variability of the ORF of
the genes to be studied and to various other criteria that assure probe specificity. As a rule
of thumb they are 1000bp probes from the 3 prime UTR. One reaction cocktail provides
sufficient probe to be dissolved into the Ambion ISH Buffer (300mL per slide, final
concentration of 100ng/mL). The probes were allowed to hybridize at 60°C over-night.
Procedure for obtaining the in vitro transcribed hapten labeled RNA Probe: The
immunological detection procedure is described for the detection of a digoxygenin
labeled RNA probe designed for the detection of specific gene transcripts. Standard
labeling methods were used, varied as explained below depending upon the DNA source
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that would provide the template for the in vitro transcription of the hapten labeled
antisense RNA probe. The digoxygenin was detected with an anti-digoxygenin antibody
coupled to peroxidase, which initiated the tyramide signal amplification step. As a result
of the signal amplification, tyramide bound biotins are crosslinked to electron rich
structures, like proteins and nucleotides in the vicinity of the specific transcript. Which
then are detected by a neutravidin antibody coupled alkaline phosphatase. The alkaline
phosphatase is what creates the precipitate out of the chromogenic substrates. With the
help of an amplification step based on enzyme catalyzed reporter deposition we believe to
have increased our sensitivity 1000 fold (Adams 1992).  Antisense RNA probes with a
length of 1000 nucleotides provide best results. It is important to ensure the probes are
not too long, as it may be difficult for longer probes to penetrate the sample, although this
is a greater problem with whole mount RNA ISH procedures, it is less of a problem while
using sections. Even probes of  2 to 3kb in length have given us good results. One must
take care to prevent cross reactivity against other homologous genes. Longer probes
could also require a higher stringency washing temperature, so the Tm must be checked
carefully. If the gene specific templates have arrived as a DNA template directly go to
step 2. Otherwise the following steps are taken;
1. Primer design and reverse transcription: After the gene specific sequence,
which will be the template for the later in vitro transcription reaction, is determined, 20-
24 base long primers bordering this sequence region should be designed. Keep in mind
that they fulfill the conditions required for a good primer. Then the sequence of the T7 or
SP6 universal primers, with 3 extra bases (GCG) to the 5' end of the forward primer and
the 3' end of the reverse primer are attached to allow the polymerase to bind better.
(Important; please take care to attach the T7 primer to the forward and the SP6 to the
reverse primer). The annealing temperature depends on the sequence of the gene specific
part of the primer because the T7 (GCG-TAATACGACTCACTATAGGG) or Sp6
(GCG-ATTTAGGTGACACTATAG) sequences play no role in binding to the mRNA.
Therefore, paste only the gene specific part of the primer in any program to determine the
annealing temperature (either local or on the web). To determine the best annealing
temperature, run an analytical (gradient) PCR with 6 tubes in a range of 20 degrees (PCR
efficiency may change according to various cyclers).  For the first PCR (using the RT
product as template), 20µL reactions for 35 cycles should be carried out and 5µL of this
reaction used for electrophoretic analysis. Do not forget the T7 and Sp6 or T3 primers
(depending on the vector) used need to have the extra 3 bases (GCG) for better RNA
polymerase binding. If some of the PCR's show the desired band, those PCR's are pooled
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and purified with Qiagen's PCR purification kit (or equivalent). If there are other bands
present, all left over samples are mixed and run on an agarose gel, the desired band is
excised and the DNA purified with a gel extraction kit.  250ng are used for  sequencing
thus verifying the PCR product. If the sequence that will be used as a template for RNA
transcription has already been sub cloned into a vector, 50ng of this DNA is taken and
used for the reamplification process. The PCR is carried out at 60°C with a gradient up to
65°C with 3 tubes. 20µL reactions for 35 cycles should be carried out and 5µL used for
electrophoretic analysis (Figure 7A).  The sequences of all the probes are available as
metadata on genepaint.org.
Table 3. Typical gradient program used in cycler:
Nr. Temp (°C) Time (min) Cycles Gradient
1 94 2.00 1
2 94 0.20
3 60 0.20
4 72 1.10
34 10°C
5 72 9.00 1
4 Pause
Table 4. PCR reaction
H2O 6.9-7.9µL
10x Buffer 2µL
Q (enhancer) 4µL
dNTPs (2 mM, Roche) 2µL
Primer for (5 pmol/µL) 2µL
Primer rev (5 pmol/µL) 2µL
Template (RT-product) 1-2µL
Enzyme Taq-Polymerase (Qiagen) 0.1µL
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Figure 7. The first PCR, second PCR and reverse transcription (A) Gradient PCR showing
band of interest around 1KB, “+” symbolizing the DNA standard. The first gradient PCR (using
the RT product as template)  carried out as a 20µL. The desired PCR products are the bands at the
higher temperature of the gradient. (B) Second PCR later used as template for the in vitro RNA
transcription. (C) Sense and antisense RNA obtained from the in vitro RNA transcription of the
DNA template.
2. Template preparation: In order to prepare template for the RNA probe, a new
100µL PCR is carried out using the purified 1st PCR product as template (described
above). If the probe has already arrived as a DNA template this can be treated as the 1st
PCR product. Either the same primers as for the first PCR (now the Tm will be much
higher because there will be a 100% match) or primers designed for sequencing can be
used. The first alternative is preferable because on one side, primers designed for
sequencing are shorter and therefore have lower Tm, and on the other, they lack the extra
bases at the 5'end which are added to enhance the stability of the polymerase binding. Of
course the first approach can be used for probes that have already arrived as DNA
template. From the product of this preparative PCR, 5µL are analyzed on an agarose gel
and the rest is purified with Qiagen's PCR purification kit and finally  eluted with 25µL
of buffer (10mM tris, pH8.5).  3µL are used to measure the concentration and determine
DNA purity.  Typically yields are in the range of 200-400ng/µL. See Figure 7B.
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Table 5. Second PCR reaction
H2O ~37.5µL
10x Buffer 10µL
Q (enhancer) 20µL
dNTPs (2 mM, Roche) 10µL
Primer for (5 pmol/µL) 10µL
Primer rev (5 pmol/µL) 10µL
Template (RT-product) ~2µL (20-50 ng)
Enzyme Taq-Polymerase (Qiagen) 0,5µL
3. In vitro RNA transcription: Currently the Strategene RNA transcription kit is
used. 1µg of template DNA that was obtained as explained above is used for this
procedure. The following are added up to a total volume of 20µL;
Table 6. In vitro RNA transcription reaction
H2O (depc) Add up to 20µL
5 x transcription buffer 4µL
rATP 10 mM 2µL
rCTP 10 mM 2µL
rGTP 10 mM 2µL
rUTP 10 mM 1,3µL
DIG-UTP 250 nmol 0,7µL
DTT 0,75 M 2µL
RNasin 40 U/µL 1µL
RNA Polymerase (T3 or T7 or SP6) 50 U/µL 0,5µL
Template 1 µg ~
DEPC water is added to obtain a volume of 20µL. The relevant RNA polymerase was
purchased as follows; T3 from Strategene, T7 and SP6 from NEB. The reaction mix was
incubated at 37°C for 4 hours and then the following were added to stop the reaction and
remove the DNA template:
Table 7. DNAse treatment of in vitro RNA transcription reaction
H2O (depc) 16,4µL
MgCl2 (0,3 M) 1,6µL
DNaseI (10 U/µL) 2,0µL
The reaction is incubated for 30 minutes at 37°C after DNAse I addition. Then was
precipitated the mix with 72µL of NH4 Acetate (4M) and 470µL of absolute ethanol.
RNase free solutions were used. After adding the solutions store at -80°C for 30 minutes
and centrifuge 10000g at 4°C. The salt was washed away with ice-cold 70% ethanol.
Then the precipitate was eluted in 25µL of DEPC water and 2µL is checked on a gel,
while 2µL was used to determine concentration in a photometer. After checking the
integrity of the RNA probe, the end volume was adjusted to 50ng/µL for each probe and
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aliquot them into 50µL volumes and store them at -80°C. Prior to usage we dilute the
probe to a concentration of 10ng/µL and store it at -20°C for a maximum of 2 months
after which it is discarded.  See Figure 7C.
4. Radioactive in vitro RNA transcription: 1µg of template DNA is used which is
obtained as explained above. The following are added up to a total volume of 20µL;
Table 8.  In vitro RNA transcription reaction
H2O (depc) Add to 20µL
5 x transcription buffer 4µL
rATP 10 mM 0,5µL
rCTP 10 mM 0,5µL
rGTP 10 mM 0,5µL
S35 rUTP (Amersham) 10mCi/mL 5µL
DTT 0,75 M 1µL
RNasin 40 U/µL 1µL
RNA Polymerase (T3 or T7 or SP6) 50 U/µL 0,5µL
Template 1 µg ~
DEPC water is added to obtain a volume of 20µL. The reaction mix is incubated at 37°C
for 4 hours and then the following are added to stop the reaction and remove the DNA;
Table 9. DNAse treatment of in vitro RNA transcription reaction
H2O (depc) 16,4µL
MgCl2 (0,3 M) 1,6µL
DNaseI (10 U/µL) 2,0µL
The reaction is incubated for 30 minutes at 37°C after DNAse I addition. The RNA was
precipitated with 72µL of NH4 Acetate (4M) and 470µL of absolute ethanol. RNase free
solutions were used. After adding the solutions store at -80°C for 30 minutes and
centrifuge 10000g at 4°C. The salt was washed away with ice-cold 70% ethanol. Then the
precipitate was eluted in 25µL of DEPC water and 1µL  was removed to a scintillation
vial with the appropriate cocktail. CPM measurements were taken in a LKB Wallac 1209
Rackbeta Liquid Scintillation counter. The Beckman Ready Flow III Liquid Scintillation
Cocktail was used for the procedure.  Prior to usage the probe was diluted to a
concentration of 50000CPM/µL.  200µL was added per slide in the standard hybmix. The
radioactive RNA ISHs were removed from the robot after the stringency washes. Rinsed
in water and dehydrated in a series of ethanol. Air dried and stored in boxes until further
processing. The sequence and other metadata related to the probes used are available at
genepaint.org (eg. Irx1, Dtx1, Colba1, Btg3,  Nurr1, Itsn,  Npy,  Clic6 and Sh3bgr).
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d. Post hybridization washes to remove non-specifically bound probe and detection of the
hapten-labeled probe (Automated):
Post hybridization washes are used to remove the non-specifically bound and unbound
probes from the tissues, thus decreasing the background and preventing nonspecific
signal from occurring, all the following post hybridization steps are at 65°C:
1. Wash 5 times for 6 minutes with 300mL wash solution 1 (5x SSC) (1x SSC, 0.3M
NaCl 0.03M sodium citrate trisodium citrate dehydrate pH 7.0).
2. Wash 5 times for 6 minutes with 300mL of wash solution 2 (2x SSC, 50%
formamide).
3. Wash 5 times for 6 minutes with 300mL of wash solution 3 (1x SSC, 50%
formamide).
4. Wash 5 times for 6 minutes with 300mL of wash solution 4 (0.1x SSC).
The recommended dilution of the antibodies to detect the hapten-label within the probe
(e.g., digoxygenin), indicated for the reconstitution volume (amounts are values
suggested by the supplier).
1. Wash 3 times with 250µL of NTE (0.05% Tween 20, 5mM EDTA,  10mM Tris,
500mM NaCl, pH 7,6)
2. Incubate 2 times at room temperature, for 5 minutes each, by applying 250µL of,
20mM iodoacetamide diluted in NTE . Iodoacetamide decreases the background by
removing the activity of various endogenous enzymes
3. Wash 3 times with 250µL of NTE
4. Incubate 2 times at room temperature, for 45 minutes each, by applying 250µL of
heat-inactivated 4% sheep-serum (Chemicon International) in TNT solution (0.05%
Tween 20 in 100mM Tris 150mM NaCl, pH 7,6) (filter before use, 0,45µm). This
solution is to decrease the background by preventing non-specific binding of the
antibody.
5.  Wash 8 times with 250µL of  TNT solution
6. Incubate 2 times at room temperature, for 30 minutes each, by applying 250µL of
TNB blocking buffer (0.05% Tween 20 in 100mM Tris 150mM NaCl, 0,5% blocking
reagent (PerkinElmer Lifesciences)  pH 7,6) (filter before use, 0,45µm). This solution
also decreases the non-specific binding of the antibody.
7. Incubate 2 times at room temperature, for 45 minutes each, by applying 250µL of
Roche's Anti-Dig-POD diluted in TNB blocking buffer (1:500 diluted in TNB, filter
through  0,45µm pore filter before adding antibody)
8. Incubate 8 times at room temperature, for 5 minutes each, by applying 250µL of TNT
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9. Incubate 2 times at room temperature, for 15 minutes each, by applying 250µL of
Tyramide-Biotin diluted with NEN amplification diluent buffer for use with tyramide
signal amplification (TSA) (PerkinElmer Lifesciences)
10. Wash 8 times with 250µL of maleate wash buffer (MWB) (100mM Maleate, 150mM
NaCl, 0.05% Tween 20, pH 7,5)
11. Incubate 2 times at room temperature, for 30 minutes each, by applying 250µL of
Neutravidin-alkaline phosphatase conjugate (Pierce) diluted in 1% blocking reagent
(Roche) containing MWB (1:600 dilution in 1% blocking reagent containing MWB,
filter through  0,45µm pore filter before adding antibody)
12. Wash 8 times with 250µL of maleate wash buffer (MWB) (100mM Maleate, 150mM
NaCl, 0.05% Tween 20, pH 7,5)
13. Wash 2 times with 250µL of  TNT solution
14. Incubate 3 times at room temperature, for 20 minutes each, by applying 250µL of
TMN solution (0.1M Tris, 0.05M MgCl2, 0.1M NaCl, 0.05% Tween, pH 9,5)
containing BCIP (1:250) NBT (1:200) (Roche)  containing levamisol (0.5mg/mL)
(Sigma). This step maybe extended depending on signal strength. Levamisol is for
the inhibition of various mammalian alkaline phosphatases (Van Belle, 1972).
15. Wash 4 times with 250µL water (0.05% Tween)
16. Wash with 250µL TNT twice
17. Fix for 20 minutes with 4% PFA, 0,5% glutaraldehyde (Sigma) containing PBS (with
0.05% Tween) by applying 250µL twice
18. Wash 4 times with 250µL PBS (with 0.05% Tween)
19. Wash 4 times with 250µL water (with 0.05% Tween)
20. Let the slides air dry overnight and cover slip them the next day with aqueous cover
slipping medium (Hydromatrix). Cover slipping is also carried out in a robot (Figure
8A). After cover slipping the extra cover slipping medium is cleaned. The slides are
labeled and ready for microscopic analysis.
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Figure 8.  (A) Cover slipping robot (B-C) microscope with motorized stage and camera
e. Microscopic analysis of the sample, image acquisition and the image archive:
The signal of a non-radioactive ISH is observed as a dark blue signal that is imaged
digitally in a bright field microscope at a magnification adjusted to single cell resolution.
The massive amount of data generated by the ISH robot requires effective and automated
image data acquisition. The fundamental issue to consider in image data collection is that
of resolution. Although it is possible to increase the resolution where subcellular
components are detectable, this is not necessary while developing a transcriptome atlas
(Carson et al. 2002). Data acquisition will be managed with a compound microscope
equipped with a scanning stage that accurately translocates the specimen in front of the
objective (Figure 8). Because the whole embryo section can not be captured at the
required magnification as a single image that fits into the object field of a compound
microscope, multiple images collected through the help of a motorized stage are stitched
together to produce a mosaic representing the entire section. Individual images are stored
as bitmap files.
A B C
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Figure 9. Main features of the Genepaint.org query and results page (A), the section-set
viewer (B), incremental magnifications obtained with the virtual microscope demonstrating
the capabilities of the zoom viewer (C-E).  The applet allows zooming into the mouse adult brain
specimen thus providing a detailed view of tyrosine hydroxylase expression at cellular resolution
within the dopaminergic neurons of the substantia nigra. All the HC21 orthologue mouse genes
are publicly available at genepaint.org.
Together with the website at  www.tigem.it/ch21exp the images are located on an archive
at the following web site genepaint.org (see Figure 9). Biological data is accessible on
databases located on the internet (Discala et al. 1999, Ringwald et al. 2000). Web-based
databases are an excellent means to efficiently retrieve and disseminate scientific data.
Large quantities of data from a variety of specimens require a database, which is a
powerful tool able to track data acquisition and storage. A database has been developed
that can provide all these features. The task of the database is to be able to import and
process data, allowing it to be later retrieved when required (Visel et al. 2002).
A B
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III. Results
3.1 Hapten labeled non-radioactive RNA  in situ hybridization
It is a widely held view that hapten-labeled RNA ISH ("non-radioactive ISH") protocols
are not as sensitive as radioactive RNA ISH methods. This would limit the usefulness of
non-radioactive ISH. However, methods have been developed that enhance sensitivity.
Specifically, tyramide signal amplification (TSA) allows up to 1000 fold amplification in
the signal strength (Adams 1992). This figure is an estimate based on
immunohistochemical assays on tissue sections. As TSA requires significantly more steps
than standard ISH protocols, TSA is not frequently used. In the advent of automated ISH
developed in our laboratory, this limitation can be overcome. A frequently held view of
TSA-based ISH is that it has high background. Once more automation of the ISH process
has allowed us to increase the number of washing and blocking steps resulting in a low
background and hence a favorable signal to noise ratio. In this section we exemplify the
difference of signal strength in the absence and presence of TSA amplification, illustrate
the low background of our method, compare radioactive and TSA based non-radioactive
ISH and provide a quantification of the sensitivity of the TSA method as executed in the
automated ISH system.
3.1.1. Effect of Tyramide Signal Amplification and low background
To illustrate the potent effect of TSA amplification, we subjected E14.5 mouse embryo
sections to ISH, probing mouse Pcp4 mRNA in the presence or absence of a  TSA step
(Figure 10A ). There is a remarkable difference in signal strength.  While the TSA treated
specimen shows a regional pattern of Pcp4 transcripts in the brain, such signal is virtually
absent in the specimen not processed with TSA.  This is particularly clear in the enlarged
view of the midbrain shown in Figure 10A. Also note the favorable signal-to-noise ratio
in these images. To further explore this particular point, we examined gene expression in
knock-out mice. Sections obtained from  null mutants of Ear2 (Figure 10B) and Prkcb
(Figure 10C) were compared with sections obtained from their wild type littermates. In
the case of Ear2, a weakly expressed gene, distinct signal is seen in many regions of the
embryo (Figure 10B).  In contrast, an equivalent section of an Ear2 mutant embryo is
virtually blank (Figure 10B). When high-power images of the olfactory epithelium are
compared, this dramatic difference is still seen. We extended this analysis to another
knock-out mouse in which the beta isoform of PKC was deleted (Prkcb). As can be seen
in Figure 10C there was strong signal in many regions of the adult wild type brain but the
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section of the mutant brain was once more blank. The high-powered images shown in
Figure 10C emphasize this point.
The initial 1300 nucleotide probe used for examining the Prkcb null mutant sections
contained a ~700bp stretch that had ~90% nucleic acid sequence identity with other PKC
isoforms. As can be seen in Figure 11A this probe results in a detectable signal especially
in the hippocampus, even in KO mice.  This signal obviously represents cross-
hybridization with other PKC isoforms and vanishes when a Prkcb specific probe was
used (Figure 11B).
Figure 10. Sensitivity gained from TSA and low background. (A) Using the Pcp4 gene
antisense probe RNA ISH was performed including the TSA step (left) and excluding  the TSA
step (right). (B) Ear2 mutant (mt) vs. Ear2 wild type (wt). (C) Prkcb mutant vs. Prkcb wild type.
The knockout specimens were hybridized with antisense probe of the appropriate gene;
specifically the Prkcbeta was hybridized with adult tissue specimens sectioned coronally while the
Ear2 specimens were hybridized with E14.5 sagittal sections. It can clearly be seen that the wt
specimens on the left show strong staining while the mt specimens on the right are nearly blank.
Tissue in red boxes in the low power view are shown below each specimen at high power. Cortex
(Cx).   
Results
53
Figure 11. Cross reactivity due to non specific probe. Prkcb expression in brains using either a
1300bp (A) or a 700bp (B) probe. The longer 1300bp probe has homology to Prkca and thus the
signal in the cornu ammonis (CA) stems from cross-hybridization as can be seen above (Dentate
gyrus DG). Although the null mutant tissue was expected to look blank when hybridized with the
Prkcb  probe, the image on the left side shows this was not the case. Whereas on the right image,
when the homologous region was removed from the probe, the cross-reactivity occurring in the
hippocampus had disappeared.
3.1.2 Comparison of radioactive and non-radioactive ISH
To show that the hapten labeled RNA ISH protocol used in this study was within the
range of sensitivity that is attributed to conventional (35S-UTP) radioactive RNA ISH
methods, we directly compared radioactive procedures with non-radioactive TSA
enhanced ISH. Importantly, both types of data were from the same specimens and both
were generated on the ISH robot. This comparison was done for a  panel of genes  that
included Clic6, Col6a1, Sh3bgr, Btg3, Irx1, Itsn, Npy, Nurr1 which showed a broad
spectrum of expression patterns and levels (Figures 12, 13).  Generally there was
excellent agreement between the results obtained by the two methods. Clic6 was locally
expressed in the choroid plexus which is obvious with both methods. Col6a1 shows
expression in various parts of the heart.  Note the strong signal in the mitral valve,
apparent in both types of preparation. Sh3bgr (Sh31da) shows uniform expression in
cardiac smooth muscle. Btg3 transcripts were in a few cells migrating within the
midbrain, bordering the cerebellum. Blue-stained cells are well visible in the non-
radioactive specimen as are the silver grains resulting from 35S ISH. Irx1 is expressed
within the tegmentum in a graded fashion as is apparent with both methods. Thus even
gradients of gene expression can be revealed by the non-radioactive procedure. The same
point was made from Itsn that not only shows very specific expression in the cortical
plate but also a quantitative difference between cortex and thalamus. Npy was expressed
in isolated cells within the inferior colliculus and these cells were seen in great detail with
the non-radioactive ISH but less clearly with the autoradiograph. Nurr1 was expressed in
the midbrain hindbrain junction, most probably within the dopaminergic neuron
precursors. This emerges from both types of data.
Results
54
Figure 12.  Radioactive vs. non-radioactive ISH panel 1. Starting from the first row from top to
bottom; Row 1; Clic6 is locally expressed in the choroid plexus. Row 2; Col6a1 shows expression
in the mitral valve of the heart (black arrow). Row 3; Sh3bgr (Sh31da) shows uniform expression
in cardiac smooth muscle. Row 4; Btg3 is in a few cells migrating along the cerebellum. The first
column shows the non-radioactive RNA ISH. The second column is a high-power view of a
specific region indicated by a red arrow in the left column. The third column shows the results of
radioactive RNA ISH for the selected region.
Taken together, our investigations point out that the TSA non-radioactive procedure was
certainly equivalent to the radioactive ISH.  In fact, the procedure was in several aspects
superior. First, it has an advantage where the signal was observed with cellular resolution.
This was difficult to achieve with the radioactive procedure because the signal arises
through autoradiography in an emulsion that overlies the section. Second, the procedure
was much faster. Even in the case of weakly expressed genes, the expression data was
viewed in less than 24 hours after starting the analysis. Third, the inherent danger of
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working with radioactive compounds and the problems related to their disposal are
circumvented.
Figure 13. Radioactive vs. non-radioactive ISH panel 2. Row 1; Irx1 is expressed within the
tegmentum (black arrow). Row 2; Itsn shows very specific expression in the cortical plate (black
arrow) and a relatively weaker signal in the thalamus (T). Row 3; Npy is expressed in isolated cells
within the inferior colliculus. Row 4; Nurr1 is expressed in the midbrain hindbrain junction, most
probably within the dopaminergic neuron precursors. The first column shows the non-radioactive
RNA ISH. The second column is a high-power view of a specific region indicated by a red arrow
in the left column. The third column shows the results of radioactive RNA ISH for the selected
region.
3.1.3 Quantification of the copy number of Dscr3 transcripts in extracted mRNA
from P7 brain sample using real-time PCR
To assess the sensitivity (copy number per cell) of the ISH using hapten labeled RNA, the
detection limit of this method was quantified by measuring the number of transcripts
present in a defined tissue volume using quantitative PCR. For this purpose a uniformly
expressed gene (Dscr3) was chosen, that in the ISH analysis gave a weak but detectable
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signal (Figure 14A, B). In a first step, three postnatal P7 brains of littermates were
dissected and a piece of brain tissue was collected corresponding to a near-rostral quarter
portion of the brain (see Figure 14C). One brain was embedded in  OCT for later
sectioning with a cryostat. The two other specimens were used for DNA and RNA
extraction. mRNA was isolated from the brain tissue using an oligo dT procedure. The
DNA was isolated using standard extraction techniques.  The quantitative PCR will allow
an estimate of the amount of  Dscr3 transcripts, while DNA quantification permits an
estimate of cell number in the tissue piece.  Finally, the microscopic analysis of sections
prepared from the remaining tissue piece allowed a second,  independent estimate of cell
number. mRNA was isolated from brain tissue using the Dynabeads Oligo (dT)25
procedure. The Ambion Competitor Construction Kit was used to generate a Dscr3 RNA
standard with a known number of RNA copies per unit volume. The synthetic RNA
referred to as 'competitor RNA' was purified, the concentration measured and the copy
number was calculated using the following formula:
purified competitor RNA (CPM/µL)  x  3x1014 molecules of rATP/µL        =  copies of competitor RNA/µl
transcription reaction (CPM/µL)            # of ATP's in the competitor RNA
5578.1        x    3x1014    =   4.2869x1010 copies of competitor RNA/µL 
339452.2            115
Figure 14. Quantification of a low expressed gene. (A) A coronal section of a P7 mouse brain is
represented. This tissue was hybridized with the Dscr3 RNA probe. (B) Magnification of A. It is
easy to see the granular precipitation of NBT-BCIP arising from alkaline phosphatase activity.
This signals that there are Dscr3 transcripts within the vicinity of the granule. (C) A diagram of a
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postnatal P7 mouse brain where the near-rostral portion of the brain corresponding to the collected
piece of tissue is painted in black. This piece of brain tissue was removed for use in the described
experiments. (D) A cell with ~11µm diameter is shown. The lines depict the diameter of the cells.
To better see the cell, a section subjected to ISH with a NPY probe was added.
Real-time PCR amplification was carried out in an iCyler iQ (Biorad) to determine the
mRNA copy number for the Dscr3 gene in the tissue sample. A preliminary analysis
using the Dscr3 competitor RNA as a standard at 10 fold serial dilutions was followed by
a second, optimized analysis in which the concentration of the standard encompassed that
of the RNA obtained from the brain extract.  The preliminary analysis yielded
approximately 1.5x10+07 copies of Dscr3 RNA per 2µL (data not shown). The optimized
analysis was carried out using a Dscr3 RNA standard bracketing this concentration. This
real-time PCR showed that the unknown sample contained 1.4 ± 0.5x10+07 copies per 2µL
(Figure 15).  Since the total volume of the mRNA extract was 30µl and the extraction
efficiency was approximately 50% (as determined by OD measurement), the total number
of Dscr3 mRNAs in the piece of brain used was estimated to be 4.2x10+08 copies.
Figure 15. Optimized quantitative PCR analysis to determine the copy number of transcript
from the Dscr3 gene. (A) The chart showing a plot for each PCR reaction based upon its relative
florescence unit (RFU). Baseline subtraction is made at the lowest point where linear
amplification of the PCR  reactions is occurring. (B) The standard curve with Dscr3 competitor
RNA was obtained by plotting of signals in (A) for three concentrations of standards (blue points,
each concentration was examined in three replicates). Similarly, the unknown was analyzed in
serial dilutions and parallel replicates. Using the Icycler IQ Optical System statistical analysis
A
B
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software (version 3.0a) the quantitative PCR yielded approximately 1.4x10+07 copies of Dscr3
RNA per 2µL of unknown sample.
To determine the number of Dscr3 mRNA molecules per cell, we next determined the
cell number in the tissue samples. This was done in two different ways. First, we
estimated the number of cells using the DNA content per cell. Second, we estimated the
cell number per section in a 20µm thick section and extrapolated this estimate to the
number of cells in the entire piece of brain tissue that was used for mRNA extraction.
DNA-based cell count: The DNA content of the brain piece was determined as 333.36µg
(Figure 14C). Since the diploid DNA content of a mouse cell is 3pg, the brain piece
contained  ~1.1x108cells.
Morphometry based cell count: First, the tissue piece was sectioned with a cryostat at a
thickness of 20µm. Then the area of each section was determined in the microscope. On
the average, each cell measures approximately ~1250µm3 [(~11.6)3µm3] (Figure 14D).
The tissue piece consisted of approximately 256 sections, and the tissue volume was ~
1.7x1011µm3.  Therefore, these measurements yield ~1.36x108 cells in the tissue piece.
The cell count estimates ranging between 1.1 and 1.36x108 (average is 1.23 x108) and the
copy number of Dscr3 mRNA molecules determined by quantitative PCR now allow one
to estimate the number of mRNA molecules present per cell. Recall that the tissue sample
contained 4.2x10+08 copies of Dscr3 mRNA.  Thus there are
4.2x108 copies      =      ~3.4 copies per cell
          1.23.x108 cells
We conclude that a weak signal as exemplified by Dscr3 (Figure 14 A, B) was caused by
as few as 3 molecules of Dscr3  mRNA.  Therefore, the non-radioactive ISH procedure
used for the present work is very sensitive similar to the sensitivity reported for 35S based
ISH (Speel et al. 1998).
3.1.4 Improved ISH performance using optimized probes
In some cases, instead of using commercially available clones as templates (such as was
done for most probes used in this study), hapten labeled RNA probes were generated by
RT-PCR based procedure (described in Section 2.2.13). The improvement in the results
was outstanding for the HC21 orthologue mouse genes IFNGR2, RUNX1, DYRK1A,
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GRIK1, and JAM2 when probes were used that were derived from a specifically designed
PCR template. The expression patterns revealed by the old and new (RT-PCR based)
mouse Ifngr2 gene probe template are shown in Figure 16. These data show the
importance of proper probe design. The new probe does not contain a poly A tail, is 200
nucleotides longer and contains less 3 prime untranslated region compared to the old
probe.
Figure 16.  Ifngr2 gene expression detected by two different probes. (A) The specimen
hybridized with the old probe (made from clone template) had high ubiquitous expression with no
expression (B-C) The specimen analyzed with the RNA probe made from the specifically designed
template showed regional expression in the cortical plate (red box and black arrow) and in the
medulla (red arrow).
3.2 Gene expression atlas of the mouse orthologues of the majority of human
chromosome 21 genes   
In the previous section the enhancement that increases the sensitivity of the ISH protocol
we use was illustrated. We also provided an estimate of the number of transcripts this
method can detect. Finally the non-radioactive protocol was compared to a conventional
radioactive ISH protocol. After assuring that the protocols were optimized to a degree
where the ISH protocol is now useful, the method was tested by cataloguing the
expression patterns of all the mouse orthologues of the HC21 genes. This effort thus
represents the first large-scale application of the automated non-radioactive ISH
technology to a biological problem.
199 cDNA fragments representing 150 mouse orthologues of the human chromosome 21
genes were isolated for ISH experiments that were carried out on sagital sections of
embryonic day 14.5 mouse embryos. Due to the fact that nearly all the organs and tissues
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have completed their development makes this a very important stage when analyzing
genes expressed in DS relevant organs (brain, heart, skeleton, gut, thymus, pancreas).
Therefore this high resolution expression “atlas” of an entire human chromosome is an
important step towards the understanding of gene function and of the pathogenetic
mechanisms in DS.
The fact that there was a vast amount of data produced in the course of the expression
analysis of the genes of a whole chromosome, it was important to be able to present the
data in a meaningful manner. Aiming to provide an interface that would satisfy the needs
of users with different backgrounds and expertises, an interface capable of achieving this
goal was designed. Therefore as a first step it was necessary to verbally annotate the
expression patterns of the mouse orthologues of the HC21 genes. This way scientists
working to find a solution for congenital heart defects would have the opportunity to
easily overview genes expressed within the heart at the investigated stage. The annotation
process was detailed as far as possible by dividing the organs into substructures. This was
done by trying to reach a balance between a detailed and informative annotation and time
constraints inherit to the annotation effort. Highest priority was given to trying to include
the most relevant and important DS organs. Then the annotation of the genes was
presented in a table, that preserves the chromosomal order of the HC21 genes. A web
page was designed and made public for the easy access of expression data (images,
annotation tables and experimental metadata) for the “human chromosome 21 gene
expression atlas”. The web site “www.tigem.it/ch21exp”  is described in appendix 7.1.
Table 10 represents an example annotation table that can be found on this website. This
table provides information on where the Btg3 gene is expressed in the E14.5 mouse
embryo. The annotation criteria can be explained as follows: if the signal was regional,
like Itsn expression in the cortical plate of the telencephalon it was assigned an “r” for
regional expression (Figure 17A). When the gene was expressed everywhere in the
relevant tissue or structure in question it was considered ubiquitous “u” (Figure 17B). In
the case for the H2bfs gene, where isolated “positive” cells across the tissue were
observed, the gene was assigned an “i” for isolated expression (Figure 17C). The signal
strength was scored according to the following levels of expression: three stars (***) for
strong expression as was observed for the Itsn gene in the cortical plate (Figure 17D,
black arrow), two stars for medium expression (which was lower compared to the strong
expression in the cortical plate of the same section) seen for Itsn expression in the
thalamus (Figure 17D, red box). One star for weak  expression, such as that observed for
the Dscr3 gene in the pons (Figure 17E). When the gene (Cxadr expression in medulla)
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did not show expression it was not scored (Figure 17F). The Btg3 gene has also weak
ubiquitous expression along with patterning. This is why it has an “ubiquitous *” sign in
the overall tissue expression box. The whole table was also shaded in light grey which is
darker when the signal strength is stronger (e.g. ubiquitous **).
Table 10. Example annotation of the Btg3 gene.
gene name Btg3
ISH number 06/02-1
Specimen Ex75.1
Tissue quality **
Overall Tissue expression ubiquitous *
Forebrain ** R
Midbrain  
Hindbrain ** R
Cerebellum *** I
Spinal cord *** I
  
Cranial ganglia  
Dorsal root ganglia  
Parasympathetic ganglia  
  
Eye  
Nasal/olfactory epithelium  
Cochlea  
  
Skeleton (cartilage)  
Lungs  
  
Atrium  
Ventricles  
Arterial system  
  
Gut  
  
Bladder  
Kidney  
  
Testis  
Ovary  
Salivary  
Spleen  
Pancreas  
Adrenal  
Thyroid  
Thymus  
Liver  
Skin  
Whisker follicles  
Muscles  
Mesenchyme  
Toungue  
 Limbs  
Tail  
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Figure 17. Annotation of the signal intensity and pattern observed for expression. (A) Itsn
(intersectin) showing strong (***) regional (R) expression in the cortical plate (red arrow) of the
telencephalon.  (B) Nnp1 expression in the hypothalamus exemplifies strong and ubiquitous “u”
expression. (C) The H2bfs gene is expressed in isolated cells across the tissue and was assigned an
“i” for isolated expression (red arrows pointing to isolated cells in the red box). (D) The signal
strength was scored three stars (***) for strong expression, as was observed for the Itsn gene in the
cortical plate (black arrow),  two stars for medium expression  for Itsn expression in the thalamus
(red box). (F) One star for weak  expression, such as that observed for the Dscr3 gene in the pons.
When the gene (Cxadr expression in medulla) did not show expression it was not scored.
3.2.1 Statistics
The analysis of the 6500 tissue sections generated for this HC21 atlas provides the
following statistical overview. Expression was detected for 64% of the genes examined at
embryonic day 14.5. Regional gene expression was observed in 42% of the genes (see
Figure 18). The highest number of genes with a restricted expression pattern were
observed in the brain and the gut. Ubiquitous expression was observed in 13% of the
cases. Genes with both weak ubiquitous and strong regional expression were observed in
9% of the cases. No expression was detected for 36% of genes.
Results
63
Figure 18. Distribution of expression patterns at embryonic day 14.5. In this pie-chart each
slice represents the percentage of genes belonging to the four categories of expression patterns
observed.
The resolution of the technology at hand, allows the study of genes showing regional
expression within organs and tissues. The well developed organ structure of the
embryonic day 14.5 embryo made it possible to visualize the expression of the human
chromosome 21 mouse orthologue genes within DS affected organs. Brain, heart, gut,
limbs, thymus, pancreas are organs that have been related to the DS phenotype. Figure 19
is a pie chart showing genes that have regional expression within these organs. The
highest percentage of regional expression was observed  in the brain (44%) for the human
chromosome 21 orthologue mouse genes. This was followed by the gut with 17% of the
genes, the heart, limbs and the thymus have an equal slice of 10% and the pancreas had
the lowest slice with 9% of the genes. In the next section expression in these tissues will
be discussed in relation to the DS pathology.
13%
42%
9%
36%
ubiquitous throughout all tissues
regional expression pattern
ubiquitous with regional expression pattern
Categories
no expression - non detectable expression
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Figure 19. Regional expression observed in Down syndrome affected organs. The slices of the
pie-chart correspond to the percentage of genes showing regional expression in DS related organs
at embryonic day 14.5 via RNA ISH.
3.2.2 Genes expressed within the brain
Certain DS phenotypes are not observed in every single DS patient. For example, only
40% of DS patients have congenital heart defects. By contrast, mental retardation is a
phenotype which is present in all DS individuals. This phenotype is associated with the
brain. The brain is involved in carrying out mental functions, where it is known that
Down patients have a lower intelligence quotient (IQ) compared to normal individuals.
Mental retardation, is the below normal level of intellectual functioning and the decreased
capability for adaptive behaviour. Stereological counting techniques have revealed that
the second phase of cortical development and the emergence of cortical lamination are
both delayed and disorganized in DS fetuses. Striking cellular changes in the DS brain are
observed in newborns and infants. They have shorter  dendrites, a decreased number of
spines with altered morphology and a defective cortical layering. Studies have also shown
delayed myelination, fewer neurons, lower neuronal density, and delayed synaptogenesis
(Engidawork and Lubec 2003).
Another defect involving the brain of DS patients is that they show the pathological
changes observed in people with Alzheimer disease. Although Alzheimer is usually
observed at old age in normal individuals, DS patients show the disease symptoms after
their third decade. Early onset Alzheimer disease is a very important disease related to
neuronal degeneration occurring through the accumulation of amyloid plaques. The
above mentioned factors, which have been associated to defects arising in the brain,
encouraged the necessity of a panel that represents genes expressed within the developing
brain at embryonic day 14.5 (Figures 20-26).
17%
 44%
10%
9%
10%
10%
gut
brain
thymus
pancreas
limb
sheart
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Figure 20.  First panel of genes expressed within the brain.  Most of the genes in the panel
were expressed in the cortical plate Rbm11 (red arrow), Stch1 (red arrow), Nrip1 (red arrow),
Ncam2 (red arrow), App (red arrow) and the ventricular zone Btg3 (black arrow), Jam2 (black
arrow) of the telencephalon. Btg3 also showed expression in a few specific cells migrating down to
the cerebellum from the midbrain (red arrow). Adamts1 was locally expressed within the choroid
plexus (red arrow). Ncam2 (black arrow), Mrps39 (black arrow) and Nrip1  (black arrow) also
showed expression in the midbrain hindbrain junction.
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Figure 21. Second panel of genes expressed within the brain. A number of the genes in the
panel were expressed in the cortical plate (Cct8  (red arrow), Cldn8 (red arrow),  Hunk1 (red
arrow)) or the ventricular zone (Sod1 (red arrow) and Rack17  (red arrow)) of the telencephalon.
Adamts5 (red arrow) was locally expressed within the choroid plexus. Grik1 shows local
expression in the developing cerebellum  (red arrow) and in the midbrain hindbrain junction
(black arrow). Cct8  (black arrow) also shows expression in the midbrain hindbrain junction.
Synj1 shows broad expression with patterning where transcript levels are very high in the brain.
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Figure 22. Third panel of genes expressed within the brain. The genes Ifngr2 (red arrow),
C21orf4 (red arrow), Itsn (red arrow), Atp5o (red arrow)  which are represented in the figure were
expressed in the cortical plate.  The genes Gart and Donson were expressed in the ventricular zone
of the telencephalon. Kcne2 was expressed within the choroid plexus  (red arrow). Cryzl1  shows
broad expression in the whole brain. Ifngr2 was also expressed in a streak of cells in the midbrain
(black arrow).
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Figure 23 Fourth panel of genes expressed within the brain. Hmgh1 , Dscr3,  Igsf5  and Wrb
show uniform expression in the brain.  Pcp4 shows expression in the cortical plate (red arrow),
developing cerebellum (red box) and in the midbrain hindbrain junction  (black arrow). Girk2 was
also expressed in the developing cerebellum (red arrow) and the midbrain hindbrain junction
(black arrow). C21orf5  (red arrow) and Ttc3 (red arrow) were expressed in the cortical plate.
Caf1a (black arrow) was expressed in the ventricular zone of the telencephalon.
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Figure 24. Fifth panel of genes expressed within the brain. Dscam (red arrow), Pde9a (red
arrow)  and Tsga2 (red arrow)  show expression in the cortical plate. Pknox (black arrow), Ndufv3
(black arrow), Wdr4 (black arrow) are expressed in the ventricular zone of the telencephalon.
Tsga2 was also expressed within the choroid plexus. Bace2 is expressed in the thalamus (red
arrow).  Ankrd3 show broad expression in the brain.
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Figure 25. Sixth panel of genes expressed within the brain. U2af1 (red arrow), Tmem1 (red
arrow) and Cstb (red arrow) show expression in the cortical plate. Ube2g2 (black arrow), PfkL
(black arrow) and H2bfs (black arrow) are expressed within the ventricular zone of the
telencephalon. Pdxk was expressed in a streak of cells in the midbrain  (red arrow). Pcbp3 was
expressed in the dorsal root ganglia, olfactory bulb  (red arrow), medulla and a streak of cells
stretching into the cerebellum from the midbrain (black arrow).
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Figure 26. Seventh panel of genes expressed within the brain. S100b was expressed in the
midbrain hindbrain junction (black arrow) and in the medulla. Pcnt2  (black arrow) was expressed
within the ventricular zone of the telencephalon, while Hrmt1l1 (red arrow) was expressed within
the cortical plate.
3.2.3 Genes expressed within the heart
One of the major causes for death among people with DS is congenital heart disease.
Congenital heart disease is observed in 40% of people with DS. 39% of the children
affected by DS have been reported to have atrioventricular defects among other cardiac
lesions. Apart from congenital heart disease related to DS, chromosome 21 has also been
associated to other heart diseases like Long QT syndrome, Ullrich disease, Knobloch
syndrome and Bethlem myopathy, and thus provides an important model to link
individual genes to pathways controlling heart development. Figure 27 represents the
genes showing expression in the heart at embryonic day 14.5. Pfkl was strongly expressed
in the ventricular wall and atrium in the developing heart. Kcnj15 and Adarb1 were
expressed in the aortic valve and trunk, while Kcnj15 was also expressed along the
outflow track of the heart and in the superior vena cava. C21orf7  shows expression within
the aortic trunk. Atp50 and Sh3bgr transcripts were detected throughout the heart. Col18a1
was only detected in cardiac vessels. Col6a1 and Col6a2 were strongly expressed in the
mitral valve and along the pericardium.
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Figure 27. Expression analysis in the developing heart. E14.5 sections were probed for Adarb1,
Atp50, Col6a1, Col18a1,  Kcnj15, PfkL, and Sh3d1a genes.  The region portrayed from the
embryo is schematically represented in the bottom right panel.  Sh3d1a (Sh3bgr) and Atp50
transcripts are detected throughout the heart. Adarb1 mRNA is restricted to the mitral valve (black
arrow), aortic valve and the endothelium of the aortic trunk (red arrow).   Pfkl was expressed
throughout the heart. Kcnj15 transcripts are found in the aortic  (red arrow) and mitral valves.
Col6a1 was strongly expressed in the mitral valve  (red arrow) and along the pericardium, whereas
Col18a1 and Ets2 expression was seen in the vessels of the heart. Adamts1 (red arrow), Adamts5
(red arrow) and C21orf7 (red arrow) all show expression within the aortic trunk, while Pcbp3 was
expressed within the peripheral nervous system  (red arrow).
3.2.4 Genes expressed within the limbs
The most apparent if not the most serious of the DS phenotypes is that all patients have
dysmorphic features. DS fetuses exhibit a reduced growth rate of limb long bones during
the third trimester of pregnancy. Limb defects like a broad gap between the second and
first toe, short broad hands and a non-ossified or hypoplastic middle phalanx of the fifth
digit are present in these fetuses (Epstein 1995). For this reason  Figure 28 represents
genes expressed within the limbs at embryonic day 14.5.  Erg has strong expression in the
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posterior proximal mesoderm and in the joints. Ets2 is also expressed in the skeletal
system. Adamts1 is expressed in the perichondrium of the developing bones.
Figure 28. A panel of genes expressed within the developing limb. Erg transcripts were present
in the posterior proximal mesoderm and in the joints. Adamts-1,  Adamts5 and Clic6 show
expression in the perichondrium of the developing digits. H2bfs showed expression within the
ridges of the digits. Col6a1, Col6a2, Ets2 and PfkL show specific expression within the joints.
While Jam2 (red arrow) and Pcp4 (red arrow) were expressed in the tendons of the limbs. S100b
was expressed within the cartilage of the limbs.
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3.2.5 Genes expressed within the digestive tract
The digestive tract is well differentiated at E14.5 and the expression of genes can be
easily detected. DS patients have a high frequency for gastrointestinal abnormalities such
as duodenal stenosis, Hirschsprung's disease, gastroesophageal reflux and imperforate
anus  (Epstein 1995). The mouse genes Atp50, Cldn8, Clic6, and Ets2 were expressed
within the endothelium of the duodenum. The Tff3 and Sod1 transcripts were present in a
subgroup of cells within the gastro duodenal junction region of the pyloric sphincter with
some expression in the endothelium of the stomach and the intraperitonal portion of the
midgut, respectively.
Figure 29. Panel of genes expressed within the gastrointestinal tract. Atp50, Cldn8, Ets2,
Clic6, Gart, Hmgh1, Kiaa0179, PkfL, Pkk, Igsf5, Tmprss2 and Wrb were expressed within the
endoderm of the duodenum. Ets2 transcripts were also detected in the vasculature surrounding the
duodenum. Sod1 mRNA was present in the midgut endoderm and in the stomach endothelium
Tff1, Tff2, Tff3 were transcribed within a subgroup of cells within the gastro duodenal junction
region of the pyloric sphincter. Pcp4, S100b and Pcbp3 were expressed within the peripheral
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nervous system. Sh31da (Sh3bgr) was expressed in the smooth muscles of the intestines. Col6a1
and Col6a2 show expression within the basal end of the duodenum.
3.2.6 Genes expressed within the thymus
Infection and malignancy are two other major causes of death for DS individuals. The
increased risk for infection seems to be caused by abnormalities in the immune system.
Compared with normal humans, DS patients show a higher incidence for certain tumors,
but they also have a lower risk for other tumor types. This symptom is associated to the
thymus which is a component of the immune system, thus in Figure 30 expression in the
thymus is presented.
Figure 30. Genes showing expression within the thymus.  Ets2 was expressed within the
vasculature of the thymus, all the other genes showed broad ubiquitous expression throughout the
thymus.
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3.2.7 Genes expressed within the pancreas
Not all but some DS patients have an annular pancreas defect, which occurs when
pancreatic tissue encircles the small intestine. This collar around the intestine causes
constriction, thus blocking or impairing the flow of food to the rest of the intestines. A
panel showing genes expressed in the pancreas at embryonic day 14.5 is presented
(Figure 31). At this stage the pancreas is not yet fully formed.
Figure 31.  Genes showing expression in the developing pancreas.  
3.2.8 Phenotypic comparison of Down with Williams Syndrome
As the expression analysis of the HC21 genes was proceeding, we had the opportunity to
analyze the genes in a deletion region linked to Williams syndrome. Williams syndrome
occurs from the heterozygous deletion of a ~1.6Mb segment from the human
chromosome 7q11.23. Although DS is caused by an extra copy of all the genes on HC21
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and Williams syndrome results from the absence of one copy of genes, both these
disorders have similar defects (Table 11). Both disorders have their specific phenotypes,
too, but there seems to be a correlation between the genome, transcriptome and disease
phenotypes, where some genes might be involved in shared regulatory pathways. Table
11 was modified from http://www.orpha.net where the mutual features of Down and
Williams Syndrome were extracted from a long list of phenotypes.
Table 11. Phenotypic comparison of Down with Williams Syndrome
Down Syndrome Williams Syndrome
clinodactyly of fifth finger clinodactyly of fifth finger
congenital cardiac anomaly complex heart disease (cardiac septal defect)
flat face flat cheek bones
short/small nose flattened nose
mental retardation mental retardation
macrocephaly microcephaly
microdontia microdontia
mouth held open mouth held open
simian crease simian crease
thick lips thick lips
We found that some of the DS and Williams syndrome genes had overlapping expression
patterns. The mouse orthologue genes of the intersectin gene located on HC21 (DS) and
the syntaxin1a gene located on chromosome 7q11.23 (Williams syndrome) have very
similar expression patterns at E14.5. At this critical developmental stage other genes like
elastin and C21orf7 also have overlapping gene expression patterns in the outflow tract of
the heart. Figure 32 illustrates the similarity between the expression patterns for the above
mentioned genes. Elastin and C21orf7 are expressed in the heart where elastin has been
associated to atrioventricular defects in the heart which are also observed in DS patients.
Intersectin and syntaxin1a are expressed in the brain, and mental retardation is a shared
phenotype between Down and Williams syndrome.
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Figure 32.  Similarity between the expression patterns for Down and Williams syndrome
genes.  Both the elastin and C21orf7 gene were expressed in the aortic trunk (red and black box).
The expression for the intersectin and syntaxin 1a gene in the central and peripheral nervous
systems was very similar.
3.2.9 Implications of clustering for regulation of expression
The significance of the expression atlas of HC21 genes in relation to genetic disorders is
obvious. Illnesses occurring through mishaps that affect one or more genes located on
HC21 will eventually be pinpointed, allowing us to prevent or treat these diseases. Based
on expression patterns it can easily be seen that the misregulation of the HC21 genes, as
in the case of DS, may cause mental retardation. The expression of the genome is
orchestrated to permit the proper and natural development of an organism. Through
communication carried out  across various levels of genomic hierarchy the  orchestration
of gene expression is achieved with cis and trans regulatory elements. The sequential
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arrangement of the genes could provide a mechanism for their coordinated regulation
through regulatory elements that steer coordinate transcription of genes, which might be
simultaneously required at a certain stage of development. This is what might be
occurring for the 9 gene cluster which is illustrated in Figure 33. These 9 genes are on the
HC21 syntenic region on mouse chromosome 16. The site of expression of these genes is
presented in Figure 34. All 9 genes are expressed in the brain, where 8 of the 9 genes
show patterning within the brain. Some of the expression patterns are identical (Ifngr2,
Itsn and C21orf4) while some are complementary (Donson and Itsn). Since the
expression patterns of all these genes do not perfectly match, signifying co-expression in
the same tissue, it is not easy to suggest a functional relationship.
Figure 33. A group of consecutive genes showing expression in the brain. The genes located in
the box; Ifngr2, C21orf4, Rps5L, Gart, Donson, Cryzl1, Itsn and Atp50 show regional expression
in the brain, except for Son which is ubiquitously expressed. All genes are on the HC21 syntenic
region on mouse chromosome 16.
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Tissue quality ** ** ** ** ** ** ** ** **
Telencephalon **R **R **R *R *U *R *R **R **R
Diencephalon 0 0 *U 0 *U 0 0 0 *U
Mesencephalon *R *R *U *R *U *U *R **U **U
Rhombencephalon **R **R **R 0 *U *U *U **U **U
Cerebellum 0 0 *U 0 *U 0 0 0 *U
Spinal Cord **R **R *U *R *U *U *R **U **R
Choroid plexus 0 0 *U 0 *U 0 0 0 *U
Cranial Ganglia **U **U *U *U *U *U *U **U *U
Dorsal Root Ganglia **U **U *U *U *U *U *U **U **U
Parasympathetic ganglia **U **U *U *U *U 0 *U **U *U
Figure 34. Sites of expression of  Ifngr2, C21orf4, Rps5L, Gart, Son, Donson, Cryzl1, Itsn and
Atp50. These genes are located on the same mouse syntenic block on chromosome 16, and they
show the same clustering on the HC21. All genes in the cluster seem to show expression in the
peripheral and brain.
Because of the similarity in the pattern of expression we utilized bioinformatics to search
for conserved sequences within the 5’ region of the cluster genes (up to 20kb). We
searched for small (under 100bp) conserved sequences within the same species
(intragenomic), for the group of nine consecutive genes (Ifngr2, C21orf4, Rps5L, Gart,
Son, Donson, Cryzl1, Itsn and Atp50). Among the clustered group of genes 2 conserved
sequences were found (the following genes are not 100% conserved among all genes, the
percentage drops to ~90%) :
Sequence 1:
gagacagggtttctctgtgtagccctagctgtcctggaactcactctgtagaccaggctggactcaaactcagaaaaccgcctgcctctgcctc
ccaagtgctgggattaaaggcgatcgccaccacacccagctt
 Sequence 2:
gagcggggcgtggtggcgcacgcctttaatcccagcactcgggaggcagacgcaggcagatttctgagttcgaggccagcctgatctacag
agtgagttccaggacagccagggctacacagagaaaccctgtctcg
These sequences have ~91% identity to each other at the nucleotide level and are not
specific to the cluster genes, they were also found in the 5’ region of other genes. A
successive cross-species (mouse-rat-human) sequence comparison was carried out for the
two sequences. A ~100 nucleotide region is conserved among rat and mouse within the 5’
of the cluster of genes with ~80% identity at the nucleotide level. A smaller 49 to 55 base
pair region is conserved among human and mouse within the 5 prime of the cluster of
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genes with ~90% identity at the nucleotide level. The region showing conservation
among mouse, rat and human might therefore be the critical regulatory domain.
To better observe the layout of the cluster genes on the chromosomes and visualize the
distribution of sequence 1 and 2 amongst these genes figures were prepared using data
provided from ENSEMBL. The mouse, rat and human syntenic regions were determined.
From Figures 35-37 the varying length of the syntenic regions can be seen. The distance
the exons of the genes are spanning is shown with blue lines, and 5’ to 3’ orientations are
indicated with red arrows. The positions for sequence 1 (green) and sequence 2 (pink) are
shown for both mouse (16) and human (21) chromosomes. It can clearly be seen that
sequence 1 and 2 are not only in the 5 prime region but they are also placed among the
first and last exons. Which is a not surprising for regulatory elements. Some of the
conserved sequences were very close to each other, so it was not possible to show each
with one arrow on a diagram of such scale. Thus 3 arrow sizes were used which
correspond to 1, 2 and 3-4 repeats of sequence. Mouse sequence 1 and sequence 2 have
91% identity at the nucleotide level, and when preparing the rat figure, sequence 2 was
localizing to the same nucleotide positions sequence 1 was localizing to, which is why
both sequence 1 and 2 are illustrated with one arrow in Figure 37.
Figure 35. The organization of the clustered genes on mouse chromosome 16 (~0.6 Mb).  The
cluster genes have 5’ to 3’  orientations shown with the red arrows. The positions of sequence 1
(green) and sequence 2 (pink) are shown. The 3 arrow sizes correspond to 1, 2 and 3-4 sequence
repeats.
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Figure 36. The organization of the clustered genes on human chromosome 21 (~0.6 Mb).  The
cluster genes have 5’ to 3’ orientations shown with the red arrows. The positions of sequence 1
(green) and sequence 2 (pink) are shown. The 3 arrow sizes correspond to 1, 2 and 3-4 sequence
repeats.
Figure 37. The organization of the clustered genes on rat chromosome 11 (~1.2 Mb). The
cluster genes have 5’ to 3’ orientations shown with the red arrows. The positions of sequence 1
and 2 (yellow) are shown. The 3 arrow sizes correspond to 1, 2 and 3-4 sequence repeats.
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Finally a 0.1Mb region from mouse chromosome 1 was used as control (90000kb-
90100kb), both sequence 1 and 2 localized to this region. These findings are indicative
that the transcription of the genes in the mouse chromosome 16 gene cluster region might
be synchronized for the correct development of the brain.
3.3 GenePaint database
The ultimate aim would be to integrate an annotation interface into a database where
users will be able query genes expressed at specific stages and tissues. Web-based
databases are an excellent means to efficiently retrieve and disseminate scientific data.
The large quantities of data from a variety of specimens require a database, which is a
powerful tool able to track data acquisition and storage. An interface providing these
features has already been developed and recently the annotation interface that will display
the annotation of the  uploaded genes has been integrated. The annotation of these genes
will provide a description of how the expression is patterned (also strength) and at which
histological location within  the tissues it appears in. Later this will be merged with a
search interface that is able to query the annotation (see figure 38) of the stored genes,
thus enabling people to search for relevant data (Visel 2002). All mouse orthologues of
the human chromosome 21 genes are currently available on the GenePaint.org database
(see Appendix 7.2 for more information).
Figure 38. The  GenePaint.org database and the recently integrated annotation interface
shown in the lower left corner. The annotation of the Pcp4 can be seen in the lower left corner.
Annotation of the pattern and sites of expression will be accessible through a query interface.
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To sum things up, the usefulness of the automated non-radioactive RNA ISH technology
developed in our lab was exemplified. First  the TSA protocol that improves the
sensitivity was examined, and the gain in signal strength in presence of the TSA was
shown. The low background of the non-radioactive method was also illustrated by
comparing expression in wildtype and mutant knock-out mice, where very low
background was obtained in mutant knock-out mice when the tissue was probed for the
transcript that was knocked out. Second, to show that the automated non-radioactive
RNA ISH protocol used in this study was within the range of sensitivity that is attributed
to conventional (35S-UTP) radioactive RNA ISH methods, results obtained with
radioactive procedures were compared with non-radioactive TSA enhanced RNA ISH.
Generally there was excellent agreement between the results. Finally, using a weak but
uniformly expressed gene (Dscr3), the sensitivity, in terms of mRNA copy number per
cell of the non-radioactive RNA ISH was quantified by measuring the number of
transcripts present in a defined tissue volume by PCR. As expression was detected with
as few as 3 molecules of Dscr3  mRNA, the non-radioactive ISH procedure used for the
present work was found to be very sensitive, similar to the sensitivity reported for 35S
based ISH (Speel et al. 1998).
After demonstrating that the non-radioactive ISH protocol was optimized to a degree
where it was applicable to a biological question, the expression of the mouse orthologues
of the human chromosome 21 genes was determined. This was the first large-scale
application of the automated non-radioactive ISH technology. The objective here was to
gain functional information by localizing the transcript to tissues and organs. Since the
DS physical phenotypes have already been associated to organs like  the brain (mental
retardation), heart (congenital heart defects), skeleton (dysmorphic features), gut
(Hirschspung disease), thymus (infection and childhood leukemia) and pancreas (annular
pancreas), panels showing genes expressed in these organs were prepared. Additionally a
web page (www.tigem.it/ch21exp) was formulated and put up for the easy access of
images, annotation tables and experimental metadata for the “human chromosome 21
gene expression atlas”.
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IV. Discussion
Analysis of the sequence of the complete human and mouse genomes has provided a first
look at the approximate gene content (Lander et al. 2001, Mouse Genome Consortium
2002).  This progress gave rise to a new challenge which is the large scale analysis of
gene function. Visualizing gene expression within specific cells of known function assists
in unravelling gene function. The instrumentation to carry out genome wide analysis of
gene expression using an automated RNA ISH protocol was developed and tested. This
technology has the capability to determine and represent the expression patterns of
thousands of genes within an acceptable time scale. After demonstrating the accuracy and
reliability of the automated non-radioactive RNA ISH technology, we analyzed, as an
application, the ~200 mouse orthologues of HC21 genes, to reveal candidate genes
associated to the various DS phenotypes. The expression pattern data not only implicated
an association between candidate genes and disease symptoms, but provided evidence for
the existence of DNA control regions in chromosomes that could control gene expression.
4.1 Evaluation of the non-radioactive in situ hybridization protocol
It is believed that non-radioactive ISH is less sensitive than radioactive RNA ISH, yet
advances like a catalyzed reporter deposition (CARD) based tyramide signal
amplification technique that can be used in the non-radioactive ISH protocols, has
provided a major improvement in sensitivity (Bobrow et al. 1989).  Methods like
Northern blot and RNase protection assay rely on RNA extracted from bulk tissue. This
may result in mRNA transcripts expressed within a few specific cells to be highly diluted
making them appear rare (or non-detectable) when they are alone among many cells that
do not express this transcript at all. When radiolabeled probes are used for ISH, it can be
difficult to obtain the resolution required to identify individual cells because the signal
consists of silver grains in an autoradiographic emulsion overlaying the tissue section. By
using three independent approaches the accuracy of the automated non-radioactive RNA
ISH technology developed in our lab was shown.
The TSA step which provides a crucial increase to the sensitivity of the non-radioactive
ISH was explored. The gain in signal strength in the absence and presence of the TSA
was examined. This was done by probing two specimens, where when the transcripts in
one set of specimens were being detected, the protocol including the tyramide signal
amplification step was used. This step was left out for the second set of specimens where
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the Pcp4 gene transcripts were probed in both specimens. In the specimen which was
probed omitting the TSA enhancement step the signal nearly totally disappeared. It was
even very hard to see the tissue itself where the tissue looked as if it was not hybridized
with RNA probe and signal was very faint, only being observed in regions of strong
expression. In the protocol provided by the manufacturer it is pointed out that TSA may
result in a high background which could be because of endogenous biotin or enzymes
(alkaline phosphatase and peroxidases) that were not suitably inactivated. The automated
system allows the use of multiple pipetting steps with accurate reproducibility, thus  with
stringent washing steps and the treatment with blocking solutions containing inhibitors, a
decrease artifact background is obtained. The low background of the non-radioactive
method was explored by comparing wildtype and null mutant mice, where very low
background and no signal was obtained as expected when the tissue was probed for the
transcript that was knocked out. This was done with the Ear2 and Prkcb mutant mice.
The absence of the transcript in these knock out mice had previously been verified with
Northern blots (personal communication, Leitges, Warnecke, 2003).
Although the Prkcb mutant tissue specimen was expected to be blank, the first probe we
designed for this assay gave a significant signal in the hippocampus due to cross-
reactivity with transcripts of other PKC isoforms. Analysis of the probe sequence
revealed a 700 nucleotide long region that was conserved between Prkcb other isoforms
of the PKC family of genes. When this region was removed the cross-reactivity
disappeared and sections of Prkcb mutant brains were blank. This case shows that the
protocol works well but one needs to ensure a gene specific template (sequence content)
design.
A second approach that was taken aimed to show that the automated non-radioactive
RNA ISH protocol used in this study, compared favorably with the range of sensitivity
attributed to conventional (35S-UTP) radioactive RNA ISH methods. There was excellent
agreement between the patterns of expression when data created by the two methods were
directly compared. This comparison was done with genes exhibiting a variety of
expression patterns. Since the non-radioactive method is faster (approximately 24 hours
from beginning to the end) than the radioactive ISH, has cellular resolution, and does not
require work with dangerous radioactive compounds, radioactive methods seem to loose
their attraction. The non-radioactive ISH protocol used in this study also allows the easy
evaluation of the tissue histology, and an additional histochemical staining step required
in the case of the radioactive method are no longer necessary. When one uses silver
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grains to pick up the radioactive signal and Hoechst to stain the nucleus of the cells the
tissue has to be photographed with two microscopic settings (darkfield and fluorescence)
followed by merging the resulting images with image software. This is done by adjusting
the images to each other with software which decreases the objectivity of the data. The
precipitate and the histological staining resulting from non-radioactive ISH protocol is
observable under one microscopic setting (brightfield).
To directly examine the sensitivity of  the non-radioactive ISH protocol used in the
present study, it was necessary to quantify the detectable transcript copy numbers to
determine if the sensitivity was similar to that reported for 35S based ISH (Speel et al.
1998). Using quantitative PCR, the sensitivity (i.e. copy number per cell) of the non-
radioactive RNA ISH was estimated by measuring the number of transcripts present in a
defined tissue volume for a weak and uniformly expressed gene (Dscr3).  The total DNA
content of the tissue was used to estimate the number of cells. We found that
hybridization signal could be seen if as few as 3 molecules of Dscr3  mRNA per cell
were present which is the same range as the sensitivity reported for 35S based ISH (Speel
et al. 1998). One point to keep in mind is that the tissue specimens used in this copy
number assay were not pretreated like the sections that are used for the typical ISH
protocol. In the typical protocol, tissue sections have to go through a series of
pretreatments (fixation, acetylation, dehydration, peroxide treatment, HCl, proteinase k
digestion) before actually being hybridized with the hapten labeled probe. These
treatments probably cause the tissue to loose RNA transcripts. This would mean that the
procedure detects less than what is present in the tissue used in the PCR quantification
experiments, implying that the ISH procedure would be even more sensitive than what we
have estimated. On the other hand a difficult to account loss might be occurring when
extracting the mRNA from the tissue specimen, which would imply that we over estimate
the sensitivity.
Asan and Kugler (1995), Zreiqat and coworkers (1998) have shown that there is a linear
relationship between the amount of alkaline phosphatase and the amount of mRNA
detected in non-radioactive ISH. Together with the systematic investigations that were
carried out, the current automated non-radioactive ISH method is both qualitative and
quantitative. After assuring the readiness of the technology, the final test to further prove
this point was carried out, the technology was applied to the mouse orthologues of the
HC21 genes.
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4.1.1 Quality of in in situ hybridization data depends on the source of the DNA
template
Different IMAGE,  BMAP-EST, NIA 15K mouse cDNA and NIID clones were ordered
and  used in this study to generate hapten labeled RNA probes. To actually have such an
easily accessible cDNA resource representing the whole genome is of course an
advantage when carrying out genome-wide studies. There are however, two faces to the
coin. When working with such a vast number of clones, some get mixed up by the
suppliers that create and provide these clones especially during the rearranging process.
Hence it was necessary to sequence verify that the clones at hand were actually those that
were ordered. To obtain a gene specific template, by reverse transcription followed by
subcloning and sequencing, is time consuming. Moreover, the resulting clones will have
to be made linear for subsequent in vitro transcription. The whole process was
streamlined as follows;
1. The T7 and SP6 promotor sequence was added to the gene specific primer sequence
used for RT-PCR removing the requirement to actually subclone the cDNA template
into a vector. This eliminates the need to work with bacteria, as is required with the
cDNA template subcloned into a vector plasmid. With a PCR approach it is possible
to store and later to reamplify the template of interest. This would also imply that the
step where the plasmid DNA is to be linearized with restriction enzymes before
transcribing the RNA probe, is no longer needed.
2. Another advantage of this strategy was that since the sequence of the whole mouse
and human genomes are available, one can use bioinformatics to design templates
covering specific regions of the gene of interest.
3. When designing such templates the poly A tails that can create high background as a
result of non-specific binding can be left out.
4. The probe length  which is most optimal under specific experimental conditions can
be chosen. Probe length is important because a too short probe might not give a
detectable signal. The longer probes contain more nucleotides, thus they have more
dig-UTPs, resulting in a stronger signal.
For the HC21 orthologue mouse genes IFNGR2, RUNX1, DYRK1A, GRIK1, and JAM2
new probes were redesigned based upon the above PCR strategy. These were chosen
among 15 genes that had a questionable expression pattern, as they were either
inconsistent with published data or had a high background-like signal. The improvement
in the results was remarkable. For example the new Jam2 template gave very specific
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signal. At the structural level the new probe had no poly A tail and encompassed a more
5’ region of the mRNA.
4.2 Analysis of the HC21 orthologue mouse gene expression data
By combining gene mapping with expression analysis it is possible to identify candidate
genes for human diseases (Ballabio 1993). The expression study of the HC21 mouse
orthologues thus provides a rich resource for candidate genes for both monogenic and
multigenic diseases mapping to HC21. However, the greatest impact of this study lies in
assessing the contribution of specific genes to DS traits and phenotypes. DS affects 1 out
of 700 live births and is caused by a third copy of the 21st human chromosome which
results in severe mental retardation and dysmorphogenesis of various organs (Wiltshire et
al. 1999). After a 99.7% sequence coverage of chromosome 21q was achieved revealing
178 confirmed genes and 36 predicted genes (Hattori et al. 2000) the opportunity to gain
an understanding of the pathogenetic mechanisms leading to DS was revealed. To gain a
functional perspective of the processes in which the known, novel and predicted genes on
HC21 were involved, a joint effort was put into creating a high resolution expression
“atlas” of  human chromosome 21 (Reymond et al. 2002b).
The mouse orthologues of the HC21 genes were analyzed via automated non-radioactive
ISH to gain functional information by localizing the transcript, to a tissue with a specific
function (e.g. pancreas, limbs). The fact that a gene is expressed at a particular stage of
embryonic development in a specific tissue or organ, would indicate that this gene may
have a function in that tissue or an important role in developmental regulation (Reeves
2002).
Expression was detected for 64% of the tested genes examined at embryonic day 14.5.
Regional gene expression was observed in 42% of the genes. Ubiquitous expression was
observed in 13% of the cases. Genes with both weak ubiquitous and strong regional
expression were observed in 9% of the cases. No expression was detected for 36% of
genes. Tissue distribution of regionally expressed transcripts reflects an association with
the DS phenotype. The largest portion of genes showing regional expression was within
the brain. It is only logical to predict that their misregulation (as in the case of trisomy 21)
would lead to a phenotype associated to the brain. This positive correlation is followed by
a number of genes expressed in other organs affected in Down syndrome such as the gut.
Organs like the limbs, heart and thymus also express genes in a regional manner. The
smallest portion of regionally expressed genes are found in the pancreas. The DS physical
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phenotypes have been associated to the following organs: the mental retardation
phenotype where DS patients have a lower IQ when compared to normal individuals and
Alzheimer’s disease has been associated to the brain. The DS heart defects where
atrioventricular defects in 39% of the children, and congenital heart disease is observed in
40% of the adults, has been linked to the heart. The DS dysmorphic features like
abnormal limbs, fingers and toes, arise due to defects in the skeleton. Intestinal lesions
observed among Down patients have been linked to the intestines. There are indications
that DS individuals have an altered immune system due to different risk factors for
various tumors compared to normal individuals, and because they are susceptible to
infection. For this reason, although it is not a primary critical DS organ, the immune
defects have been linked to the thymus. The annular pancreas defect observed in DS has
been associated to the pancreas.
4.2.1 Down syndrome
4.2.1.1 DS brain associated defects
Mental retardation is a feature of DS which reflects the most complicated and limiting of
its handicaps. Until now no pharmacological therapy has been shown to have a positive
effect. Although a decreased density of neurons, changes in phospholipid composition
and alterations in electrophysiological properties of the brain and isolated neurons have
been studied, the specific causes for mental retardation are still not known (Epstein
1995). The numerous HC21 orthologue genes expressed in the brain, increase the risk of
a phenotype occurring in this organ due to improper development caused by
misregulation. The genes expressed at this critical time point  (embryonic day 14.5) are
important for the proper development of the brain. There are transgenic mice that have
been associated with DS. The Sod1 gene shows ubiquitous expression with strong
regional expression in the brain and spinal cord, and Sod1 transgenic animals show
learning defects (Epstein 1995). Axonal proliferation and astrocytosis is observed in the
S100ß transgenic mice (Reeves et al. 1994).
Another defect observed in the brain of Down patients is that they show the pathological
changes observed in people with Alzheimer disease (Busciglio et al. 2002, Frederikse and
Ren 2002, Head et al. 2002, Motonaga et al. 2002). Although Alzheimer is usually
observed at old age in normal individuals, DS patients show the disease symptoms after
their third decade. Early onset Alzheimer disease is a very important disease related to
neuronal degeneration occurring through the accumulation of amyloid plaques. Like the
amyloid precursor protein gene (APP) which has already been associated to early onset
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Alzheimer disease, other HC21 genes showing regional expression in the brain like
SYNJ1, S100B, NRIP1, TTC3, CCT8,GRIK1, KCNJ6, IFNGR2, HUNK and PCP4 are
candidates for further studies to solve this disease. Beta site amyloid precursor protein
cleaving enzyme (BACE2) is another HC21 gene which has been linked to Alzheimer
which shows expression in the brain (Benett et al. 2000). Understanding Alzheimer might
even help us gain insight into other common diseases that occur through neuronal
degeneration such as Parkinson disease. All the above mentioned genes are also
expressed in the midbrain-hindbrain junction which has been associated to dopaminergic
neurons, which degenerate in Parkinson disease patients.
4.2.1.2 DS heart associated defects
One of the major causes for death among people with DS is congenital heart disease.
Congenital heart disease is observed in 40% of people with DS. 39% of the children
affected by DS have been reported to have atrioventricular defects among other cardiac
lesions (Epstein 1995). In particular, ADARB1, KCNJ15, PFKL, C21ORF7, ETS2 and
SH3BGR are promising candidate genes for the DS heart abnormalities because their
murine orthologues are expressed in the developing heart. Apart from congenital heart
disease, HC21 has also been associated to other heart diseases like Long QT syndrome
and Bethlem myopathy, and thus provides an important model to link individual genes to
pathways controlling heart development. The genes of HC21 are expressed in particular
regions of the heart during embryonic development; therefore these regionally expressed
genes may have a role in heart defects found in Down patients. Patients with the
following heart disease have mutations in the following genes: Bethlem myopathy
patients have mutations in COL6A1, Ullrich disease patients have mutations in COL6A2
and Knobloch syndrome patients have mutations in COL18A1 (Abbott et al. 1999, Sertie
et al. 2000).  As stated in literature, Col18a1 was detected in both cardiac blood vessels
and blood vessels of the whole body. Col6a1 and Col6a2 were strongly expressed in the
mitral valve and along the pericardium as already has been described (Camacho Vanegas
et al. 2001, Higuchi et al. 2001, Jobsis et al. 1996).
4.2.1.3 DS skeletal defects
An easily recognizable, albeit a less serious DS phenotype, is that all patients have
dysmorphic features. DS fetuses exhibit a reduced growth rate of limb long bones during
the third trimester of pregnancy.  Limb defects such as a gap between the second and first
toe, short, broad hands and a non-ossified or hypoplastic middle phalanx of the fifth digit
has been observed in these fetuses (Epstein 1995). Several genes of HC21 were
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regionally expressed in the limbs at embryonic day 14.5. Erg has strong expression in the
posterior proximal mesoderm and in the joints. Ets2 was also expressed in the skeletal
system and was previously found to result in skeletal abnormalities reminiscent of DS
when overexpressed in transgenic mice (Sumarsono et al. 1996). Adamts1 was expressed
in the perichondrium of the developing bones. Although the limb phenotype is as striking
as that of mental retardation, only 10% of the genes examined showed regional
expression in the limbs. One possibility is that the few genes regionally expressed in the
limbs are involved in a network which does not allow misregulation.
4.2.1.4 DS gastrintestinal abnormalities
DS patients have a high frequency for gastrointestinal abnormalities such as duodenal
stenosis, Hirschsprung's disease, gastroesophageal reflux and imperforate anus  (Epstein
1995). The digestive tract is well differentiated at embryonic day 14.5 and the expression
of genes can be detected easily. The mouse genes Atp50, Cldn8, Clic6, and Ets2 were
expressed within the endothelium of the duodenum. Tff3 and Sod1 transcripts were
present in a subgroup of cells within the gastro duodenal junction region of the pyloric
sphincter, with some expression in the endothelium of the stomach and the intraperitonal
portion of the midgut, respectively. The human orthologues of the gut-expressed genes
ATP50, CLDN8, CLIC6, ETS2, KCNJ15, SH3BGR, and WRB, may thus play a role in the
DS gastrointestinal abnormalities (Kola and Herzog 1997).
4.2.1.5 DS immune system abnormalities
Infection and malignancy are two other major causes of death for DS people (Epstein
1995). These defects seem to arise through abnormalities in the immune system. Down
patients show a lower incidence of certain tumor types: neuroblastomas, and solid tumors,
a higher risk for other tumor types; leukemias, lymphomas, testicular germ cells (Satge et
al. 1998a, Hasle et al. 2000). The decreased incidence of solid tumors in individuals with
DS, indicates that the increased dosage of HC21 genes may be protecting these
individuals from these tumors (Satge et al. 1998b, Hasle et al. 2000). Satge et al. have
associated the overexpression of S100B in Down patients with the lower risk for
neuroblastomas. Loss of heterozygosity has been observed for specific regions of HC21
in several solid tumors (Sakata et al. 1997, Kohno et al. 1998, Ohgaki et al. 1998,
Yamamoto et al. 1999, Ghadimi et al. 1999, Bockmuhl 1998) including cancers of the
head, neck, breast, pancreas, mouth, stomach, oesophagus, and lung. This usually
indicates that there is at least one tumor suppressor gene in this region. Recently it has
been shown that AML1-ETO can suppress transcription of the p14arf tumor suppressor
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gene, through suppression of the AML1 (RUNX1) DNA binding site of the p14arf
promoter (Linggi et al. 2002).
4.2.1.6 DS pancreas defects
Not all, but some DS patients have an annular pancreas defect. This defect arises when
the pancreas tissue forms a ring-like collar around the intestine, preventing the further
passage of food into the digestive tract. At this stage the pancreas is still a primordia and
not well structured, thus a misregulation of the genes expressed at embryonic day 14.5
could cause the dysmorphogenesis of the pancreas.
4.2.2 Phenotypic comparison of Down with Williams Syndrome
Williams syndrome occurs from the heterozygous deletion of a ~1.6Mb segment from the
human chromosome 7q11.23. This corresponds to a 1.4Mb region in the mouse
chromosome 5 which has been sequenced with high accuracy (DeSilva et al. 2002).
Although DS is characterized by an extra copy of all the genes on HC21, and Williams
syndrome is characterized by the absence of one copy of genes, both these disorders have
similar defects. A few of the genes on both chromosomes have exhibited overlapping
expression patterns. For example, the mouse orthologues of the Intersectin gene, located
on HC21 (DS), and the Syntaxin1a gene, located on chromosome 7q11.23 (Williams
syndrome), have identical expression patterns at E14.5. Both these genes have been
associated with clathrin mediated vesicle trafficking (Pucharos et al. 2001, Metzler et al.
2001). This data raises the possibility that there is a correlation between the transcriptome
and disease phenotypes.
4.2.3 Implications for clustering of expression patterns, for shared regulation
The components of the genome are orchestrated to permit the proper and natural
development of an organism. To achieve this, the genome needs to synchronize and
influence its components through communication carried out  across various levels of
hierarchy. This could be done through the co-regulation of genes belonging to shared
regulatory pathways owing to shared non-coding sequence motifs that direct the binding
of specific groups of shared transcription factors (Li et al. 1999, Dermitzakis et al. 2002).
However there is the probability that the co-regulation of genes might be in response to
Locus Control Regions (LCRs). LCRs are novel elements, distinct from promoters,
classical enhancers, chromosomal insulator, matrix attachment regions or scaffold
attachment regions, they open the nucleosome structure so other structures can bind. They
are copy number dependant where they temporally influence expression of linked genes
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(Schreiber and Bernstein 2002, Pennacchio and Rubin 2001). The consecutive placement
of the genes on the chromosome could be to allow their coordinated regulation through an
element influencing their synchronized transcription which might be simultaneously
required at a certain stage of development.
Our attention was drawn to a group of nine genes (Ifngr2, C21orf4, Rps5L, Gart, Son,
Donson, Cryzl1, Itsn and Atp50) showing similar expression patterns in the brain. These
genes are consecutive both in the mouse and in the human chromosomes. Among these
nine genes some have expression patterns which overlap or are identical (Ifngr2, C21orf4
and Itsn), while some are complimentary (Itsn and Donson).  All nine mouse orthologues
are located on the same mouse syntenic block on chromosome 16, and they show the
same order as on the HC21. Since the expression patterns of all the genes do not overlap,
it is not easy to suggest a functional relationship between these functionally divergent
proteins. This does not exclude the possibility that they could be involved in a common
pathway.
We utilized bioinformatics to search for conserved sequences within the 5’ region of the
cluster genes (~20kb 5’ region). We searched for small (under 100bp) conserved
sequences within the same species (intragenomic). In a study the Levine lab in Berkley
(USA) showed that there are shared regulatory elements involved in the dorsal-ventral
patterning (Stathopoulos et al. 2002). We found 2 shared sequences among our clustered
group of genes. After the conserved sequences were identified the region of the
chromosome containing all the nine genes of the cluster were scanned for these
sequences. The sequence was not only found in the 5’ region, but also the introns and the
3’ regions of the group of nine genes it could be influencing.
A cross-species sequence comparison was also carried out for the two sequences and they
were also found to be conserved among rat, human and mouse to a certain degree. The
region showing conservation among mouse, rat and human might be the critical
regulatory domain. However, functional experiments (Boffelli et al. 2003) which might
allow us to determine if these are truly functional regulatory elements have not yet been
done. Nevertheless all these findings are indicative that the transcription of the genes in
this region might be synchronized for the correct development of the brain. Albeit
preliminary, this data suggest that regions containing coexpressed genes exist on HC21.
Further studies are required to verify this, but attention needs to be drawn to an extent
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that a preliminary overview acquired from genome-wide studies will allow us to obtain
the initial data for such assays.
4.3 Future directions
This study does not solve the problems that arise from the presence of a third copy of a
whole chromosome. The correlation of the HC21 gene expression patterns, and the
disease phenotypes, however, allows us to prioritize various candidate genes, which of
course can be further examined with follow up experiments. Appropriate, functional
experimental approaches will be developed, based on the type of genes that are prioritized
according to expression information gained from this study. For example, since we have
already catalogued the native expression pattern of the HC21 mouse orthologue genes,
observing the changes occurring in the mutant mice (partial trisomy 16 mouse model)
would help us understand what happens under the influence of an extra copy of the HC21
orthologue mouse genes (Sago et al. 1998).
The mouse is a suitable model organism for the study of human biology because it has a
well characterized genome, has a similar physiology, it is easy to collect specimens and
compared to human the chief difference is mainly in size and shape. Nevertheless it
should not be forgotten that trisomy 21 is a unique human disorder. To obtain conclusive
data of greater medical relevance this study might need to be followed up with
experiments using human embryo specimens. Human tissue samples are rare and
valuable, prioritizing genes through a preliminary study carried out in mouse samples
makes the whole process relatively feasible. Once these genes are verified in human
tissues they would be further prioritized e.g. as drug targets. Thus the next step would be
to carry out a bioinformatic analysis to determine the protein sequence, which would
reveal if the gene had domains identical to the already existing characteristics of proteins
that can be targeted by drugs. These would include channel proteins, G-protein coupled
receptors, secreted proteins and kinases among other proteins. With follow-up functional
studies, the biomedical relevance (diagnostics, intervention and drug therapy) of these
genes would be determined.
By itself the GenePaint database will have the well catalogued and annotated gene
expression patterns of the whole genome, which is a striking achievement all by itself.
However, in the future query interfaces where one can retrieve the data according to ones
interest, (structure, sequence, expression clustering, etc.) will be available. It will be
possible when working with specific diseases such as Parkinson’s disease to retrieve all
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the genes expressed within the substantia nigra and hence to obtain a list of putatively
interacting gene products. Since the goal is to carry this out across certain developmental
stages, the data will have developmental relevance and shall be even more informative.
The organization and linking of the data to other databases will make it even more
powerful. Now the database is linked to GenBank and GeneCards which provide
substantial background information to the gene of interest. A future goal will be to search
the database for regulatory networks that could shed light on the organization of the
genome. Insight into issues like gene clustering could be gained by linking gene
expression patterns to chromosomal location or if it were possible to identify shared
regulatory elements through various bioinformatics interfaces. Clearly, much work needs
to be done for such a large-scale database on gene expression but the present study shows
that this effort is both possible and highly promising.
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V. Conclusion
The ISH technology (GenePaint) is an integrated system which has been developed to
carry out, catalogue and store and retrieve gene expression data. Not only has the
automated process of treating the slides rapidly via in situ  hybridization been increased
to a level where a large amount of data can be produced, but the cover slipping, scanning,
data cataloguing and image retrieval interfaces (along with automated annotating
software) need to be running like the wheels of a smoothly ticking clock. I have tried to
present, what could be called, the part of the non-radioactive ISH technology which is
directly related to the wet lab experiments. Through the use of 3 approaches the reliability
of this automated non-radioactive ISH technology was explored; 1. assessing the
advantages of the TSA, 2. comparing with radioactive ISH methods and 3. quantifying
the detection limit.
After demonstrating that the non-radioactive ISH protocol was optimized to a degree
where it was applicable to a biological question, the expression of the mouse orthologues
of the human chromosome 21 genes was determined. This was the first large-scale
application of the automated non-radioactive ISH technology. The objective here was to
gain functional information by localizing the transcript to tissues and organs.With the
analysis of nearly all HC21 genes, another level of genome annotation has been reached.
Now it will be easier to pinpoint candidates genes for monogenic disorders and complex
diseases which could be used to diagnose the illness in its early stages, or even better, to
find a way to prevent the disease from occurring by intervening with its development e.g.
via gene therapy. In other words this study is another advance of research into DS and
HC21 associated disorders that helps in the search for genes of therapeutic relevance.
Last but not least, this study has provided initial insights for clustering of expression
patterns, through shared regulation.
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VII. Appendix
7.1 Brief introduction to www.tigem.it/ch21exp/
· After entering the world wide web address www.tigem.it/ch21exp the entrance page
to the “human chromosome 21 gene expression atlas”  will open up on the web
browser
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· After you enter the atlas, you can access the scientific data by clicking onto the
various headings under “scientific data”,
-summary table
-example of gene expression in specific tissues
-materials and methods
A guide on how to use this site can be accessed under the heading “how to use this
site”.
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· After clicking on the “summary table” link the page showing the summary table
which has all the HC21 genes listed in chromosomal order and the accession numbers
for their murine orthologues opens. When one of the HC21 genes are clicked upon,
the expression data belonging to the corresponding murine orthologue is accessible.
For example click on the link to the BTG3 gene.
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· After clicking on the “BTG3” link you can access the expression data for the BTG3
gene. Whole mount ISHs (WISH) were done for two stages; embryonic day 9.5 and
10.5. The WISH’s were done by our collaborators in Italy.  Our collaborators in
Geneva carried out the experiments for the RT-PCR experiments on different mouse
tissues. Finally, all the ISHs on embryonic day 14.5 embryo sections were done in the
Max Planck Institute in Hannover.  A larger image of the thumbnails may be
visualized by clicking on the relevant thumbnail. The verbal annotations for this gene
can also be called up by clicking on the link  “E14.5table” beneath the thumbnail.
Additional probe information can be obtained by clicking on the “probe” link, or
information on the gene can be retrieved by clicking on the “gene characteristics”
link that will retrieve the data stored on GenBank for this particular gene.
Click on thumbnail for larger image
Link to verbal annotation table
Gene characteristics via GenBank
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7.2 Brief introduction to www.genepaint.org
· After entering the world wide web address www.genepaint.org  into your browser the
home page to the GenePaint database will be produced. The gene symbol for the gene
of interest is entered and then the “go” button is pressed to start the query (e.g. Sim2).
Then the next screen will pop up showing the stages that have been studied for this
gene. The database contains embryonic day 14.5 whole embryo sections, and often
also embryonic day 15.5 head sections, P7 and adult mice brain sections.
Enter gene name and
click go to initiate query
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· The results window allows an overview of stages that have been examined for the
query gene. Certain advanced query options are also presented in this window and
allow e.g. entry of DNA sequence which will then be blasted against the sequences of
the probes used for ISHs within the database. The blast results are presented from the
highest to the lowest score. The options boxes at the bottom left corner allow the
queries to be limited to certain developmental stages.
Instead of a gene name a sequence may be used
for the querying of the database
The query could be limited to a certain
developmental stage
The setviewer
initiates the data
viewing window
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· Results are viewed by clicking the setviewer option. The resulting window shows an
interface with metadata (left side), presenting experimental conditions and sequence
information. Below the infobar are two buttons that link to the GenBank and
GeneCard databases. On the right side of the screen there is a thumbnail of the
section of interest, and by choosing one of the viewer options (html format, applet
interface or a downloadable plug-in software) one is able to examine the section
shown in the thumbnail with the help of an “electronic microscope”. The images can
rapidly be browsed using the forward  and reverse arrow button.
Buttons link to GenBank and
GeneCard
Metadata
Sections representing various levels of the embryo
Various options to view the sections with
the zoomviewer
Button for browsing through
listed images in the directory
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· Example depicting a section that is being viewed with the applet viewer. The small
window that has popped up has various tools at the bottom that assist in viewing. The
(+) button enables zooming in, the (-) button enables zooming out, the hand allows
panning, and the magnification button (+) brings up a small window allowing a
magnification of a specific section within the total image.
Tools that assist in viewing
(+) zoom in
(-) zoom out
(the hand) panning
magnification window
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